

Supplementary Information

Screening of a virtual mirror-image library of natural products

Taro Noguchi, Shinya Oishi,* Kaori Honda, Yasumitsu Kondoh, Tamio Saito, Hiroaki Ohno,
Hiroyuki Osada, and Nobutaka Fujii*

*Graduate School of Pharmaceutical Sciences, Kyoto University
RIKEN CSRS*

Contents

Experimental procedures	S2-S20
LC–MS chromatograms of synthetic proteins (Fig. S1)	S21
Mass spectrometry data of synthetic proteins (Fig. S2)	S22
CD spectra of synthetic proteins (Fig. S3)	S23
SPR analysis of p53 binding to synthetic MDM2 proteins (Fig. S4)	S23
Data of the initial chemical array screening (Table S1)	S24
Structures of hit compounds (Fig. S5)	S25
Inhibitory activities of reference compounds (Table S2)	S25
Inhibitory activity of <i>ent</i> -NP843 by SPR analysis and ELISA (Table S3)	S25
Representative dose-response curves of competitive inhibition assays (Fig. S6)	S26
Results of cell growth inhibition assay (Fig. S7)	S27
NMR Spectra	S28-S67

Experimental Procedures

General Methods. ^1H NMR and ^{13}C NMR spectra were recorded using a JEOL ECA-500 spectrometer. Chemical shifts are reported in δ (ppm) relative to Me₄Si (in CDCl₃) and residual THF (in THF-*d*₈). ^{13}C NMR spectra were referenced to the residual CHCl₃ (in CDCl₃) and THF (in THF-*d*₈). ^1H NMR spectra were tabulated as follows: chemical shift, multiplicity (br: broad, s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet), number of protons, and coupling constants. Exact mass (HRMS) spectra were recorded on a JMS-HX/HX 110A mass spectrometer or Shimadzu LC-ESI-IT-TOF-MS equipment. Melting points were measured by a hot stage melting point apparatus (uncorrected). For flash chromatography, Wakogel C-300E (Wako) was employed. For analytical HPLC for MDM2 proteins, Cosmosil 5C18-AR300 (4.6 × 250 mm, Nacalai Tesque Inc.) was employed with a linear gradient of CH₃CN containing 0.1% (v/v) TFA aq. at a flow rate of 1 cm³ min⁻¹. Cosmosil 5C18-ARII column (4.6 × 250 mm, Nacalai Tesque Inc.) was employed for the analysis of the other peptides.

Synthesis of MDM2^{25–109} and MDM2^{TMR} Proteins

L-MDM2^{25–109}, L-MDM2^{TMR}, D-MDM2^{25–109} and D-MDM2^{TMR} proteins were synthesized by the identical protocol in our previous report.¹ Briefly, protected MDM2^{25–109} was synthesized by a standard protocol of Fmoc-based SPPS using automatic peptide synthesizer (PSSM-8, Shimadzu Corporation Ltd.) on H-Rink Amide-ChemMatrix resin (0.4–0.6 mmol g⁻¹) using HBTU/HOBt/ (*i*Pr)₂NEt activation. The resulting protected peptide resin was treated with TFA/thioanisole/ *m*-cresol/1,2-ethanedithiol/H₂O (80:5:5:5) at room temperature for 2 h. After removal of the resin by filtration, the filtrate was poured into ice-cold dry Et₂O. The resulting powder was collected by centrifugation and then washed with ice-cold dry Et₂O three times. The crude product was purified by HPLC to provide MDM2^{25–109} proteins as white powder.

For the synthesis of MDM2^{TMR} proteins, two glycines and 5-hexynoic acid were coupled with HBTU/HOBt/(*i*Pr)₂NEt. The resulting protected peptides were treated with the deprotection cocktail as above to provide alkyne-conjugated proteins. Subsequently, treatment of the proteins with TMR-(PEG)₃-azide in the presence of Cu(I) provided TMR-labeled MDM2^{TMR} proteins as pink powder.

ESI-TOF MS for L-MDM2^{25–109}: Calcd for C₄₆₂H₇₃₉N₁₁₇O₁₂₃S₄: 10027.42; observed: [M+12H]¹²⁺ *m/z* = 836.74, [M+11H]¹¹⁺ *m/z* = 912.76, [M+10H]¹⁰⁺ *m/z* = 1003.86, [M+9H]⁹⁺ *m/z* = 1115.39, [M+8H]⁸⁺ *m/z* = 1254.76, [M+7H]⁷⁺ *m/z* = 1434.00.¹

ESI-TOF MS for D-MDM2^{25–109}: Calcd for C₄₆₂H₇₃₉N₁₁₇O₁₂₃S₄: 10027.42; observed: [M+12H]¹²⁺ *m/z* = 836.68, [M+11H]¹¹⁺ *m/z* = 912.77, [M+10H]¹⁰⁺ *m/z* = 1003.94, [M+9H]⁹⁺ *m/z* = 1115.46, [M+8H]⁸⁺ *m/z* = 1254.85, [M+7H]⁷⁺ *m/z* = 1433.42.

ESI-TOF MS for L-MDM2^{TMR}: Calcd for C₅₀₅H₇₈₉N₁₂₅O₁₃₃S₄: 10865.79; observed: [M+13H]¹³⁺ *m/z* = 836.94, [M+12H]¹²⁺ *m/z* = 906.78, [M+11H]¹¹⁺ *m/z* = 989.03, [M+10H]¹⁰⁺ *m/z* = 1087.90, [M+9H]⁹⁺ *m/z* = 1208.38, [M+8H]⁸⁺ *m/z* = 1359.59.¹

ESI-TOF MS for D-MDM2^{TMR}: Calcd for C₅₀₅H₇₈₉N₁₂₅O₁₃₃S₄: 10865.79; observed: [M+13H]¹³⁺ *m/z* = 836.65, [M+12H]¹²⁺ *m/z* = 906.65, [M+11H]¹¹⁺ *m/z* = 989.11, [M+10H]¹⁰⁺ *m/z* = 1088.17, [M+9H]⁹⁺ *m/z* = 1208.45, [M+8H]⁸⁺ *m/z* = 1359.80.

Folding of Synthetic MDM2^{25–109} and MDM2^{TMR} Proteins

Folding of synthetic MDM2 proteins were carried out by the identical protocol in our previous report.¹ Lyophilized polypeptide was dissolved in 6 M Gu·HCl (1 mg cm⁻³) followed by 100-fold dilution with PBS (pH 7.4) containing 0.5 mmol dm⁻³ TCEP·HCl and 0.005% Tween-20 at 4 °C. The solution was stored at 4 °C overnight, and the solution was concentrated using a MWCO 3000 centrifugal filtration membrane (Millipore, Amicon-Ultra 3 kDa) (3 times).

Synthesis of p53 Peptides and Their Derivatives

p53 peptides were synthesized by Fmoc-SPPS on Rink-amide resin (0.66 mmol g⁻¹, 45.5 mg, 0.025 mmol) according to the identical protocol in our previous report.¹ Fmoc-protected amino acids (3 eq) were coupled by using DIC (3 eq) and HOBr (3 eq) in DMF. The Fmoc-protecting group was removed by treatment of the resin with 20% piperidine in DMF. Coupling of biotin (0.125 mmol) was carried out with HBTU (5 eq), HOBr (5 eq) and (Pr)₂NEt (10 eq) in DMF. Coupling of 5-carboxyfluorescein (5 eq) was carried out with DIC (5 eq) and HOBr (10 eq) in DMF. The resulting protected peptide resin was treated with TFA/thioanisole/*m*-cresol/1,2-ethanedithiol/H₂O (80:5:5:5:5) at room temperature for 2 h. After removal of the resin by filtration, the filtrate was poured into ice-cold dry Et₂O. The resulting powder was collected by centrifugation and then washed with ice-cold dry Et₂O three times. The crude product was purified by HPLC on a Cosmosil 5C18-ARII preparative column (Nacalai Tesque, 20 × 250 mm). All peptides were characterized by ESI-MS or MALDI-TOF-MS.

Biotin-labeled L-p53 peptide (biotinyl-aminocaproyl-GSGSSQETFSSDLWKLLPEN-NH₂): MS (MALDI-TOF) calcd for C₁₀₈H₁₆₆N₂₇O₃₅S [M+H]⁺ 2434.19; found: 2434.13.¹

Biotin-labeled D-p53 peptide: MS (MALDI-TOF) calcd for C₁₀₈H₁₆₆N₂₇O₃₅S [M+H]⁺ 2434.19; found: 2434.12.


L-P4 (H-LTFEHYWAQLTS-NH₂): MS (MALDI-TOF) calcd for C₇₁H₁₀₀N₁₇O₁₉ [M+H]⁺ 1494.74; found: 1494.75.¹

D-P4: MS (MALDI-TOF) calcd for C₇₁H₁₀₀N₁₇O₁₉ [M+H]⁺ 1494.74; found: 1494.73.^[1]

5-Carboxyfluorescein-labeled L-P4 (5-FAM-LTFEHYWAQLTS-NH₂): MS (MALDI-TOF) calcd for C₉₂H₁₁₀N₁₇O₂₅ [M+H]⁺ 1852.79; found: 1852.80.¹

5-Carboxyfluorescein-labeled D-P4: MS (MALDI-TOF) calcd for C₉₂H₁₁₀N₁₇O₂₅ [M+H]⁺ 1852.79; found: 1852.76.

Synthesis of NP843 Derivatives 12a-d




Methyl (R)-2-Methyl-3-(trityloxy)propanoate (S2).² To a stirred solution TrtCl (23.5 g, 169 mmol) in CH₂Cl₂ (150 cm³) were added Et₃N (17.9 cm³, 186 mmol), DMAP (1.03 g, 16.9 mmol), (R)-Roche ester (**S1**, 4.69 cm³, 42.3 mmol) at room temperature. After the mixture was stirred overnight, saturated NH₄Cl was added. The whole was extracted with CHCl₃ and the extract was washed with H₂O and brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure. Recrystallization from EtOH gave the title compound **S2** as colorless crystals (9.55 g, 63%): mp 96–98 °C (from EtOH); [α]²⁵_D –16.8 (c 1.10, CHCl₃); IR (neat) ν_{max}/cm^{–1}: 1737 (C=O); δ_H (500 MHz, CDCl₃) 1.15 (3H, d, *J* 6.9, CH₃), 2.71–2.77 (1H, m, CH), 3.17 (1H, dd, *J*₁ 8.9, *J*₂ 6.0, CH₂), 3.30 (1H, dd, *J*₁ 8.6, *J*₂ 6.9, CH₂), 3.70 (3H, s, CH₃) 7.21–7.42 (15H, m, Ar); δ_C(125 MHz, CDCl₃) 14.0, 40.4, 51.6, 65.3, 86.3, 127.0 (3C), 127.7 (6C), 128.7 (6C), 143.9 (3C), 175.4. *Anal.* calcd. for C₂₄H₂₄O₃: C, 79.97; H, 6.71. Found: C, 79.76; H, 6.86.

Methyl (S)-2-Methyl-3-(trityloxy)propanoate (*ent*-S2). According to the procedure described for the preparation of **S2**, (S)-Roche ester (*ent*-**S1**, 4.69 cm³, 42.3 mmol) was converted into *ent*-**S2** as colorless crystals (9.56 g, 63%): mp 96–98 °C (from EtOH); [α]²⁵_D +16.6 (c 1.05, CHCl₃); IR (neat) ν_{max}/cm^{–1}: 1739 (C=O); δ_H(500 MHz, CDCl₃) 1.15 (3H, d, *J* 6.9, CH₃), 2.71–2.77 (1H, m, CH), 3.17 (1H, dd, *J*₁ 8.6, *J*₂ 5.7, CH₂), 3.30 (1H, dd, *J*₁ 8.6, *J*₂ 6.9, CH₂), 3.70 (3H, s, CH₃) 7.21–7.42 (15H, m, Ar); δ_C(125 MHz, CDCl₃) 14.0, 40.4, 51.6, 65.3, 86.3, 127.0 (3C), 127.7 (6C), 128.7 (6C), 143.9 (3C), 175.4. *Anal.* calcd. for C₂₄H₂₄O₃: C, 79.97; H, 6.71. Found: C, 80.05; H, 6.77.

(R)-2-Methyl-3-(trityloxy)propyl 4-Methylbenzenesulfonate (2).² To a stirred solution of compound **S2** (9.00 g, 25.0 mmol) in THF (200 cm³) under argon was added LiAlH₄ (1.42 g, 37.4 mmol) at 0 °C. After the mixture was stirred for 30 min, saturated aqueous solution of sodium potassium tartrate was slowly added at 0 °C, and the mixture was stirred overnight at room temperature. The whole was extracted with Et₂O and the extract was washed with H₂O and brine, and dried over MgSO₄. Filtration through a short pad of silica gel and concentration under reduced pressure gave a crude alcohol, which was used without further purification. TsCl (5.96 g, 31.3 mmol) was added to a solution of the alcohol in pyridine (18.2 cm³) at 0 °C. After the mixture was stirred overnight, the reaction was quenched with H₂O at 0 °C. The whole was extracted with CHCl₃, and the extract was washed with H₂O and brine, and dried over MgSO₄. Filtration through a short pad of silica gel and concentration gave a crude sulfonate. Recrystallization from CHCl₃/hexane gave the title compound **2** as colorless crystals (11.6 g, 96%): mp 146–148 °C (from CHCl₃/hexane); [α]²⁵_D –11.4 (c 1.15, CHCl₃); IR (neat) ν_{max}/cm^{–1}: 1360 (OSO₂), 1176 (OSO₂); δ_H(500 MHz, CDCl₃) 0.89 (3H, d, *J* 8.6, CH₃), 2.01–2.08 (1H, m, CH), 2.43 (3H, s, CH₃), 2.93 (1H, dd, *J*₁ 9.2, *J*₂ 6.9, CH₂), 3.02 (1H, dd, *J*₁ 9.2, *J*₂ 5.2, CH₂), 3.99 (1H, dd, *J*₁ 9.2, *J*₂ 6.3, CH₂), 4.12 (1H, dd, *J*₁ 9.5, *J*₂ 5.4, CH₂), 7.21–7.34 (17H, m, Ar), 7.74–7.76 (2H, m, Ar); δ_C(125 MHz, CDCl₃) 13.9, 21.6, 34.0, 64.2, 72.5, 86.4, 127.0 (3C),

127.7 (6C), 127.9 (2C), 128.6 (6C), 129.8 (2C), 133.0, 143.9 (3C), 144.6. *Anal.* calcd. for C₃₀H₃₀O₄S: C, 74.05; H, 6.21. Found: C, 73.91; H, 6.26.

(S)-2-Methyl-3-(trytyloxy)propyl 4-Methylbenzenesulfonate (*ent*-2). According to the procedure described for the preparation of **2**, compound *ent*-**S2** (8.00 g, 22.2 mmol) was converted into *ent*-**2** as colorless crystals (9.05 g, 84%): mp 145–148 °C (from CHCl₃/hexane); [α]²⁵_D +11.4 (c 1.08, CHCl₃); IR (neat) ν_{max}/cm⁻¹: 1361 (OSO₂), 1175 (OSO₂); δ_H(500 MHz, CDCl₃) 0.89 (3H, d, *J* 8.6, CH₃), 2.01–2.08 (1H, m, CH), 2.43 (3H, s, CH₃), 2.93 (1H, dd, *J*₁ 9.2, *J*₂ 6.9, CH₂), 3.02 (1H, dd, *J*₁ 9.2, *J*₂ 5.2, CH₂), 3.99 (1H, dd, *J*₁ 9.2, *J*₂ 6.3, CH₂), 4.12 (1H, dd, *J*₁ 9.5, *J*₂ 5.4, CH₂), 7.21–7.34 (17H, m, Ar), 7.74–7.76 (2H, m, Ar); δ_C(125 MHz, CDCl₃) 13.9, 21.6, 34.0, 64.2, 72.5, 86.4, 127.0 (3C), 127.7 (6C), 127.9 (2C), 128.6 (6C), 129.8 (2C), 133.0, 143.9 (3C), 144.6. *Anal.* calcd. for C₃₀H₃₀O₄S: C, 74.05; H, 6.21. Found: C, 73.86; H, 6.33.



(2*S*,6*R*)-2,6,10-Trimethylundec-9-en-1-ol (4). To a stirred mixture of Mg (1.00 g, 41.2 mmol) in THF (6.6 cm³) was added dropwise (*S*)-citronellyl bromide (**S3**, 6.00 g, 27.4 mmol) in THF (16.8 cm³) over 2 h using syringe pump at 60 °C to give Grignard reagent **3**. To a stirred solution of **2** (6.9 g, 14.2 mmol) in THF (31.0 cm³) were added the reagent **3** and Li₂CuCl₄ in THF (0.1 mol dm⁻³, 27.0 cm³, 2.70 mmol) at –40 °C. The resulting mixture was stirred at –40 °C overnight and the reaction was quenched with saturated NH₄Cl at 0 °C. The whole was extracted with Et₂O and the extract was washed with H₂O and brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure. The oily residue was dissolved in hexane and the solution was filtrated through a short pad of silica gel to give crude **S4**. To a stirred solution of the compound **S4** in dry Et₂O (120 cm³) was added HCO₂H (120 cm³) dropwise at 0 °C under argon, and the stirring was continued for 1 h. After toluene (150 cm³) was added, the solution was concentrated under reduced pressure. 1*N* NaOH in MeOH/H₂O (1:1, 100 cm³) was added to the residue and the mixture was stirred for 10 min. The mixture was concentrated under reduced pressure. The residue was extracted with Et₂O and the extract was dried over MgSO₄. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography to give the title compound **4** as a colorless oil (1.67 g, 55%). [α]²⁵_D –7.5 (c 1.10, CHCl₃); IR (neat) ν_{max}/cm⁻¹: 3319 (OH), 1035 (C-O); δ_H(500 MHz, CDCl₃) 0.86 (3H, d, *J* 6.3, CH₃), 0.93 (3H, d, *J* 6.3, CH₃), 1.04–1.42 (9H, m), 1.60 (3H, s, CH₃), 1.58–1.65 (1H, m), 1.68 (3H, s, CH₃), 1.89–2.03 (2H, m, CH₂), 3.42 (1H, dd, *J*₁ 10.3, *J*₂ 6.3, CH₂), 3.51 (1H, dd, *J*₁ 10.6, *J*₂ 6.0, CH₂), 5.09–5.11 (1H, m, CH); δ_C(125 MHz, CDCl₃) 16.6, 17.6, 19.6, 24.3, 25.5, 25.7, 32.4, 33.4, 35.8, 37.1, 37.2, 68.4, 125.0, 131.0. HRMS (FAB) calcd for C₁₄H₂₉O (MH⁺): 213.2213; found: 213.2217.

(2*R*,6*S*)-2,6,10-Trimethylundec-9-en-1-ol (*ent*-4). According to the procedure described for the preparation of **4**, compound *ent*-**2** (5.00 g, 10.3 mmol) was converted into *ent*-**4** with (*R*)-citronellyl bromide (6.40 g, 29.2 mmol) as a colorless oil (996 mg, 46%). [α]²⁵_D +7.4 (c 1.17, CHCl₃); IR

(neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 3357 (OH), 1034 (C-O); δ_{H} (500 MHz, CDCl₃) 0.86 (3H, d, *J* 6.9, CH₃), 0.92 (3H, d, *J* 6.3, CH₃), 1.03-1.41 (m, 9H), 1.60 (3H, s, CH₃), 1.58-1.65 (1H, m), 1.68 (3H, s, CH₃), 1.89-2.03 (2H, m, CH₃), 3.42 (1H, dd, *J*₁ 10.3, *J*₂ 6.3, CH₂), 3.51 (1H, dd, *J*₁ 10.6, *J*₂ 6.3, CH₂), 5.09-5.11 (1H, m, CH); δ_{C} (125 MHz, CDCl₃) 16.6, 17.6, 19.6, 24.3, 25.5, 25.7, 32.4, 33.4, 35.8, 37.1, 37.2, 68.4, 125.0, 131.0. HRMS (FAB) calcd for C₁₄H₂₉O (MH⁺): 213.2213; found: 213.2223.

(3*S*,7*R*)-3,7,11-Trimethyldodec-10-enenitrile (5**).** To a stirred solution of compound **4** (1.26 g, 5.93 mmol) in pyridine (4.3 cm³) was added TsCl (1.40 g, 7.72 mmol) at 0 °C. After the mixture was stirred for 2 h, saturated aqueous solution of citric acid was added. The whole was extracted with Et₂O and the extract was washed with H₂O and brine, and dried over MgSO₄. The extract was concentrated under reduced pressure after filtration through a short pad of silica gel to give a crude sulfonate. To a stirred solution of the sulfonate in DMSO (13.0 cm³) was added NaCN (0.581 g, 11.8 mmol) at room temperature. After the mixture was stirred overnight, saturated aqueous solution of NH₄Cl was added. The whole was extracted with CHCl₃ and the extract was washed with H₂O and brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography to give the title cyanide **5** as a colorless oil (1.17 g, 89%). $[\alpha]^{25}_{\text{D}} +5.2$ (*c* 1.02, CHCl₃); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 2247 (C≡N); δ_{H} (500 MHz, CDCl₃) 0.87 (3H, d, *J* 6.3, CH₃), 1.07 (3H, d, *J* 6.9, CH₃), 1.07-1.17 (2H, m), 1.23-1.43 (7H, m), 1.60 (3H, s, CH₃), 1.69 (3H, s, CH₃), 1.81-1.89 (1H, m), 1.89-2.03 (2H, m, CH₂), 2.23 (1H, dd, *J*₁ 16.6, *J*₂ 6.9, CH₂), 2.32 (1H, dd, *J*₁ 16.6, *J*₂ 5.7, CH₂), 5.09-5.11 (1H, m, CH); δ_{C} (125 MHz, CDCl₃) δ 17.6, 19.5 (2C), 24.2, 24.4, 25.5, 25.7, 30.5, 32.3, 36.2, 36.8, 37.0, 119.0, 124.9, 131.1. HRMS (FAB) calcd for C₁₅H₂₈N (MH⁺): 222.2216; found: 222.2224.

(3*R*,7*S*)-3,7,11-Trimethyldodec-10-enenitrile (*ent*-5**).** According to the procedure described for the preparation of **5**, compound *ent*-**4** (950 mg, 4.47 mmol) was converted into *ent*-**5** as a colorless oil (948 mg, 96%). $[\alpha]^{25}_{\text{D}} -5.3$ (*c* 1.08, CHCl₃); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 2247 (C≡N); δ_{H} (500 MHz, CDCl₃) 0.87 (3H, d, *J* 6.3, CH₃), 1.07 (3H, d, *J* 6.9, CH₃), 1.09-1.17 (2H, m), 1.21-1.43 (7H, m), 1.61 (3H, s, CH₃), 1.69 (3H, s, CH₃), 1.81-1.89 (1H, m), 1.89-2.03 (2H, m, CH₂), 2.24 (1H, dd, *J*₁ 16.6, *J*₂ 6.9, CH₂), 2.32 (1H, dd, *J*₁ 16.6, *J*₂ 5.7, CH₂), 5.08-5.11 (1H, m, CH); δ_{C} (125 MHz, CDCl₃) 17.6, 19.5 (2C), 24.2, 24.4, 25.5, 25.7, 30.5, 32.3, 36.2, 36.8, 37.0, 119.0, 124.9, 131.1. HRMS (FAB) calcd for C₁₅H₂₈N (MH⁺): 222.2216; found: 222.2224.

(3*S*,7*R*)-3,7,11-Trimethyldodec-10-en-1-ol (6**).³** To a stirred solution of **5** (1.00 g, 4.52 mmol) in CH₂Cl₂ (5.0 cm³) was added dropwise DIBAL-H in THF (1.0 mol dm⁻³, 4.97 cm³, 4.97 mmol) at -78 °C under argon. After the mixture was stirred for 2 h, saturated aqueous solution of sodium potassium tartrate was added and the mixture was warmed to room temperature. The whole was extracted with Et₂O and the extract was dried over MgSO₄. The extract was concentrated under reduced pressure after filtration through a short pad of silica gel to give crude aldehyde. To a stirred solution of the aldehyde in CH₂Cl₂ (5.0 cm³) was added dropwise DIBAL-H in THF (1.0 mol dm⁻³, 4.97 cm³, 4.97 mmol) at -78 °C under argon. After the mixture was stirred for 2 h, saturated aqueous solution of sodium potassium tartrate was added. The whole was extracted with Et₂O and the extract was dried

over MgSO₄. The extract was concentrated under reduced pressure, and the residue was purified by column chromatography to give the title alcohol **6** as a colorless oil (0.848 g, 83%). $[\alpha]^{25}_D -2.3$ (*c* 0.90, CHCl₃); IR (neat) ν_{max}/cm^{-1} : 3299 (OH), 1058 (C-O); δ_H (500 MHz, CDCl₃) 0.86 (3H, d, *J* 6.3, CH₃), 0.90 (3H, d, *J* 6.3, CH₃), 1.07-1.41 (11H, m), 1.54-1.64 (1H, m), 1.61 (3H, s, CH₃), 1.69 (3H, s, CH₃), 1.89-2.03 (2H, m, CH₂), 3.64-3.73 (2H, m, CH₂), 5.09-5.11 (1H, m, CH); δ_C (125 MHz, CDCl₃) 17.6, 19.6, 19.7, 24.3, 25.6, 25.7, 29.5, 32.4, 37.0, 37.2, 37.5, 40.0, 61.3, 125.0, 124.9, 131.0. HRMS (FAB) calcd for C₁₅H₃₁O (MH⁺): 227.2369; found: 227.2363.


(3*R*,7*S*)-3,7,11-Trimethyldodec-10-en-1-ol (*ent*-6**).** According to the procedure described for the preparation of **6**, compound *ent*-**5** (900 mg, 4.07 mmol) was converted into *ent*-**6** as a colorless oil (606 mg, 66%). $[\alpha]^{25}_D +2.0$ (*c* 1.05, CHCl₃); IR (neat) ν_{max}/cm^{-1} : 3299 (OH), 1055 (C-O); δ_H (500 MHz, CDCl₃) 0.86 (3H, d, *J* 6.3, CH₃), 0.90 (3H, d, *J* 6.3, CH₃), 1.04-1.41 (11H, m), 1.52-1.63 (1H, m), 1.60 (3H, s, CH₃), 1.68 (3H, s, CH₃), 1.89-2.03 (2H, m, CH₂), 3.64-3.73 (2H, m, CH₂), 5.08-5.12 (1H, m, CH); δ_C (125 MHz, CDCl₃) 17.6, 19.6, 19.7, 24.3, 25.6, 25.7, 29.5, 32.4, 37.0, 37.2, 37.5, 39.9, 61.3, 125.0, 124.9, 131.0. HRMS (FAB) calcd for C₁₅H₃₁O (MH⁺): 227.2369; found: 227.2363.

(6*R*,10*S*)-12-Bromo-2,6,10-trimethyldodec-2-ene (7**).** To a stirred solution of compound **6** (800 mg, 3.53 mmol) in pyridine (2.70 cm³) was added TsCl (876 mg, 4.60 mmol) at 0 °C. After the mixture was stirred for 2 h, saturated aqueous solution of citric acid was added. The whole was extracted with Et₂O and the extract was washed with H₂O and brine, and dried over MgSO₄. The extract was concentrated under reduced pressure after filtration through a short pad of silica gel to give a crude sulfonate. To a stirred solution of the sulfonate in acetone (5 cm³) was added LiBr (1.80 g, 17.7 mmol). After the mixture was stirred for 1 h under reflux, the whole was concentrated under reduced pressure. To the residue was added H₂O and the whole was extracted with Et₂O and dried over MgSO₄. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography to give the title bromide **7** as a colorless oil (923 mg, 90%). $[\alpha]^{25}_D +5.8$ (*c* 1.00, CHCl₃); δ_H (500 MHz, CDCl₃) 0.86 (3H, d, *J* 6.9, CH₃), 0.89 (3H, d, *J* 6.9, CH₃), 1.04-1.41 (9H, m), 1.61 (3H, s, CH₃), 1.68 (3H, s, CH₃), 1.61-1.68 (2H, m), 1.85-2.03 (3H, m), 3.38-3.49 (2H, m, CH₂), 5.09-5.11 (1H, m, CH); δ_C (125 MHz, CDCl₃) 17.6, 19.0, 19.6, 24.1, 25.6, 25.7, 31.6, 32.3, 32.4, 36.8, 37.1 (2C), 40.0, 125.0, 131.0. *Anal.* calcd. for C₁₅H₂₉Br: C, 62.28; H, 10.10. Found: C, 62.31; H, 10.32.

(6*S*,10*R*)-12-Bromo-2,6,10-trimethyldodec-2-ene (*ent*-7**).** According to the procedure described for the preparation of **7**, compound *ent*-**6** (580 mg, 2.56 mmol) was converted into *ent*-**7** as a colorless oil (669 mg, 90%). $[\alpha]^{25}_D -5.8$ (*c* 1.01, CHCl₃); δ_H (500 MHz, CDCl₃) 0.86 (3H, d, *J* 6.9, CH₃), 0.89 (3H, d, *J* 6.9, CH₃), 1.07-1.41 (9H, m), 1.61 (3H, s, CH₃), 1.68 (3H, s, CH₃), 1.61-1.68 (2H, m), 1.84-2.03 (3H, m), 3.38-3.49 (2H, m, CH₂), 5.09-5.11 (1H, m, CH); δ_C (125 MHz, CDCl₃) 17.6, 19.0, 19.6, 24.1, 25.6, 25.7, 31.6, 32.2, 32.4, 36.8, 37.1 (2C), 40.0, 125.0, 131.0. *Anal.* calcd. for C₁₅H₂₉Br: C, 62.28; H, 10.10. Found: C, 62.22; H, 10.08.

Triphenyl[(3*S*,7*R*)-3,7,11-trimethyldodec-10-en-1-yl]phosphonium Bromide (8**).** A mixture of the bromide **7** (757 mg, 2.61 mmol) and PPh₃ (750 mg, 2.87 mmol) was heated to 100 °C and the mixture was stirred for 15 h. After cooling, Et₂O was added to the mixture and the resulting white precipitate was washed with Et₂O to remove the excess PPh₃. The residue was dried under vacuum to give the title phosphonium salt **8**, which was used without further purification.

Triphenyl((3*R*,7*S*)-3,7,11-trimethyldodec-10-en-1-yl)phosphonium Bromide (*ent*-8**).** According to the procedure described for the preparation of **8**, compound *ent*-**7** (600 mg, 2.07 mmol) was converted into *ent*-**8**.




Benzyl (*R*)-6-(Benzylxy)-2,5,7,8-tetramethylchromane-2-carboxylate (S6**).⁴** To a stirred solution of (*R*)-Trolox (**S5**, 1.90 g, 7.59 mmol) in DMF (13.0 cm³) were added K₂CO₃ (8.38 g, 60.8 mmol) and BnBr (3.61 cm³, 30.4 mmol) at room temperature. After the mixture was stirred overnight, the reaction was quenched with H₂O. The whole was extracted with Et₂O and the extract was washed with H₂O and brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography to give the title compound **S6** as a colorless oil (3.24 g, 99%). [α]²⁵_D +38.6 (c 1.05, CHCl₃); IR (neat) ν_{max}/cm⁻¹: 1731 (C=O); δ_H(500 MHz, CDCl₃) 1.64 (3H, s, CH₃), 1.83-1.91 (1H, m, CH₂), 2.09 (3H, s, CH₃), 2.15 (3H, s, CH₃), 2.23 (3H, s, CH₃), 2.38-2.48 (2H, m, CH₂), 2.54-2.62 (1H, m, CH₂), 4.68 (2H, dd, J₁ 13.2, J₂ 11.5, CH₂), 5.04 (1H, d, J 12.6, CH₂), 5.15 (1H, d, J 12.6, CH₂), 7.09-7.51 (10H, m, Ar); δ_C(125 MHz, CDCl₃) 11.8, 11.9, 12.9, 20.9, 25.5, 30.6, 66.6, 74.7, 77.2, 117.3, 123.0, 126.0, 127.6 (2C), 127.7 (2C), 127.8, 128.0, 128.2, 128.4 (2C), 128.5 (2C), 135.7, 137.9, 148.0, 148.9, 173.7. HRMS (ESI) calcd for C₂₈H₃₀NaO₄ (MNa⁺): 453.2036; found: 453.2039.

Benzyl (*S*)-6-(Benzylxy)-2,5,7,8-tetramethylchromane-2-carboxylate (*ent*-S6**).** According to the procedure described for the preparation of **S6**, (*S*)-Trolox (*ent*-**S5**, 2.5 g, 10.0 mmol) was converted into *ent*-**S6** as a colorless oil (4.28 g, 99%). [α]²⁵_D -38.4 (c 1.27, CHCl₃); IR (neat) ν_{max}/cm⁻¹: 1731 (C=O); δ_H(500 MHz, CDCl₃) 1.64 (3H, s, CH₃), 1.83-1.91 (1H, m, CH₂), 2.09 (3H, s, CH₃), 2.15 (3H, s, CH₃), 2.23 (3H, s, CH₃), 2.38-2.48 (2H, m, CH₂), 2.54-2.62 (1H, m, CH₂), 4.68 (2H, dd, J₁ 13.2, J₂ 11.2 Hz, CH₂), 5.04 (1H, d, J 12.6, CH₂), 5.15 (1H, d, J 12.6, CH₂), 7.09-7.51 (10H, m, Ar); δ_C(125 MHz, CDCl₃) 11.8, 11.9, 12.9, 20.9, 25.5, 30.6, 66.6, 74.7, 77.2, 117.3, 123.0, 126.0, 127.6 (2C), 127.7 (2C), 127.8, 128.0, 128.2, 128.4 (2C), 128.5 (2C), 135.7, 137.9, 148.0, 148.9, 173.7. HRMS (ESI) calcd for C₂₈H₃₀NaO₄ (MNa⁺): 453.2036; found: 453.2026.

(*R*)-6-(Benzylxy)-2,5,7,8-tetramethylchromane-2-carbaldehyde (9**).⁴** To a stirred solution of compound **S6** (3.24 g, 7.53 mmol) in CH₂Cl₂ (8.2 cm³) was added dropwise DIBAL-H in THF (1.0 M,


15.2 cm^3 , 15.2 mmol) at -78°C under argon. After the mixture was stirred for 2 h, saturated aqueous solution of sodium potassium tartrate was added. The whole was extracted with Et_2O and the extract was dried over MgSO_4 . Filtration through a short pad of silica gel and concentration under reduced pressure gave a crude alcohol. To a stirred solution of $(\text{COCl})_2$ (0.881 cm^3 , 15.2 mmol) in CH_2Cl_2 (60.0 cm^3) was slowly added DMSO (1.97 cm^3 , 30.4 mmol) in CH_2Cl_2 (9.0 cm^3) at -78°C under argon. After the mixture was stirred for 15 min, the above alcohol in CH_2Cl_2 (41.5 cm^3) was added dropwise, and stirred for 30 min. Et_3N (6.36 cm^3 , 45.6 mmol) was slowly added to the mixture and the mixture was warmed to 0°C . After the mixture was stirred for 30 min, saturated NH_4Cl aq. was added. The whole was extracted with Et_2O , the extract was washed with H_2O and brine, and was dried over Na_2SO_4 . The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography. Recrystallization from $\text{CHCl}_3/\text{hexane}$ at -20°C gave the title compound **9** as white solid (1.85 g , 75%): mp $60\text{--}61^\circ\text{C}$ (from $\text{CHCl}_3/\text{hexane}$); $[\alpha]^{25}_{\text{D}} -13.6$ ($c\ 0.90$, CHCl_3); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 1737 (C=O); δ_{H} (500 MHz , CDCl_3) 1.41 (3H , s, CH_3), $1.80\text{--}1.86$ (1H , m, CH_2), 2.13 (3H , s, CH_3), 2.20 (3H , s, CH_3), 2.24 (3H , s, CH_3), $2.25\text{--}2.29$ (1H , m, CH_2), $2.50\text{--}2.63$ (2H , m, CH_2), 4.68 (2H , s, CH_2), $7.33\text{--}7.50$ (5H , m, Ar), 9.64 (1H , d, $J\ 1.1$, CHO); δ_{C} (125 MHz , CDCl_3) 11.9 , 12.0 , 12.9 , 20.2 , 21.6 , 27.7 , 74.7 , 80.4 , 117.7 , 123.1 , 126.4 , 127.7 (2C), 127.9 , 128.5 (2C), 128.6 , 137.7 , 147.4 , 149.1 , 204.4 . *Anal.* calcd. for $\text{C}_{21}\text{H}_{24}\text{O}_3$: C, 77.75 ; H, 7.46 . Found: C, 77.50 ; H, 7.49 .

(S)-6-(Benzylxy)-2,5,7,8-tetramethylchromane-2-carbaldehyde (ent-9). According to the procedure described for the preparation of **9**, *ent-S6* (3.90 g , 9.06 mmol) was converted into *ent-9* as white solid (2.10 g , 71%): mp $59\text{--}61^\circ\text{C}$ (from $\text{CHCl}_3/\text{hexane}$); $[\alpha]^{25}_{\text{D}} +12.5$ ($c\ 1.00$, CHCl_3); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 1737 (C=O); δ_{H} (500 MHz , CDCl_3) 1.41 (3H , s, CH_3), $1.80\text{--}1.86$ (1H , m, CH_2), 2.13 (3H , s, CH_3), 2.20 (3H , s, CH_3), 2.24 (3H , s, CH_3), $2.25\text{--}2.29$ (1H , m, CH_2), $2.50\text{--}2.63$ (2H , m, CH_2), 4.68 (2H , s, CH_2), $7.34\text{--}7.50$ (5H , m, Ar), 9.64 (1H , d, $J\ 1.1$, CHO); δ_{C} (125 MHz , CDCl_3) 11.9 , 12.0 , 12.9 , 20.3 , 21.6 , 27.7 , 74.7 , 80.4 , 117.7 , 123.1 , 126.4 , 127.7 (2C), 127.9 , 128.5 (2C), 128.6 , 137.7 , 147.4 , 149.1 , 204.4 . *Anal.* calcd. for $\text{C}_{21}\text{H}_{24}\text{O}_3$: C, 77.75 ; H, 7.46 . Found: C, 77.52 ; H, 7.55 .




(S)-2,5,7,8-Tetramethyl-2-((4*S*,8*S*)-4,8,12-trimethyltridecyl)chroman-6-ol (10b).⁵ To a stirred solution of phosphonium salt **8** (ca. 2.61 mmol) in THF (15.0 cm³) was added LiHMDS (1.0 mol dm⁻³, 2.30 cm³, 2.30 mmol) in THF dropwise at -40°C under argon. After the mixture was stirred for 30 min, the aldehyde **9** (675 mg, 2.08 mmol) in THF (5.0 cm³) was added to the mixture. The stirring was continued for 30 min at the same temperature and for 1 h at 0°C . After the reaction was quenched with saturated aqueous solution of NH₄Cl, the whole was extracted with Et₂O and the extract was washed with H₂O and brine, and dried over Na₂SO₄. The filtrate was concentrated under reduced pressure. The oily residue was dissolved in hexane and the solution was filtrated through a short pad of silica gel and concentrated down to give crude **S7**. To a stirred solution of **S7** in TBME (9.5 cm³) was added PtO₂ (37.8 mg, 0.167 mmol). The mixture was stirred under an atmosphere of H₂ at room temperature. After


30 min, the reaction mixture was filtrated through Celite and the filtrate was concentrated. To a stirred solution of the residue in MeOH (35.0 cm^3) was added 10% Pd/C (222 mg, 0.208 mmol). The mixture was stirred under an atmosphere of H₂ at room temperature. After 30 min, the reaction mixture was filtrated through Celite. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography to give the title compound **10b** as a pale yellow oil (759 mg, 84%). $[\alpha]^{25}\text{D} -0.7$ (*c* 1.01, CHCl₃); δ_{H} (500 MHz, CDCl₃) 0.83-0.87 (12H, m, 4CH₃), 1.02-1.53 (21H, m), 1.23 (3H, s, CH₃), 1.73-1.84 (2H, m, CH₂), 2.11 (6H, s, 2CH₃), 2.16 (3H, s, CH₃), 2.60 (2H, t, *J* 6.9, CH₂), 4.17 (1H, s, OH); δ_{C} (125 MHz, CDCl₃) 11.3, 11.8, 12.2, 19.6, 19.7, 20.7, 21.0, 22.6, 22.7, 23.8, 24.4, 24.8, 28.0, 31.5, 32.7, 32.9, 37.3, 37.4 (3C), 39.4, 39.8, 74.5, 117.3, 118.4, 121.0, 122.6, 144.5, 145.5. HRMS (ESI) calcd for C₂₉H₅₀O₂ (M⁺): 430.3811; found: 430.3806.



(R)-2,5,7,8-Tetramethyl-2-((4S,8S)-4,8,12-trimethyltridecyl)chroman-6-ol (10c). According to the procedure described for the preparation of **10b**, compound *ent*-**9** (675 mg, 2.07 mmol) was converted into compound **10c** by the reaction with **8** (ca. 2.61 mmol) as a pale yellow oil (573 mg, 57%). $[\alpha]^{25}\text{D} +1.0$ (*c* 1.10, CHCl₃); δ_{H} (500 MHz, CDCl₃) 0.83-0.87 (12H, m, 4CH₃), 1.03-1.58 (21H, m), 1.23 (3H, s, CH₃), 1.73-1.84 (2H, m, CH₂), 2.11 (6H, s, 2CH₃), 2.16 (3H, s, CH₃), 2.60 (2H, t, *J* 6.9, CH₂), 4.17 (1H, s, OH); δ_{C} (125 MHz, CDCl₃) 11.3, 11.8, 12.2, 19.7 (2C), 20.8, 21.0, 22.6, 22.7, 23.8, 24.4, 24.8, 28.0, 31.4, 32.7, 32.8, 37.3, 37.4 (2C), 37.5, 39.4, 39.8, 74.5, 117.3, 118.4, 121.0, 122.6, 144.5, 145.5. HRMS (ESI) calcd for C₂₉H₅₀O₂ (M⁺): 430.3811; found: 430.3803.




(S)-2,5,7,8-Tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-ol (10d). According to the procedure described for the preparation of **10b**, compound **9** (540 mg, 1.66 mmol) was converted into compound **10d** by the reaction with *ent*-**8** (ca. 2.08 mmol) as a pale yellow oil (573 mg, 80%). $[\alpha]^{25}\text{D} -1.0$ (*c* 1.00, CHCl₃); δ_{H} (500 MHz, CDCl₃) 0.83-0.87 (12H, m, 4CH₃), 1.03-1.58 (21H, m), 1.23 (3H, s, CH₃), 1.73-1.84 (2H, m, CH₂), 2.11 (6H, s, 2CH₃), 2.16 (3H, s, CH₃), 2.60 (2H, t, *J* 6.9, CH₂), 4.17 (1H, s, OH); δ_{C} (125 MHz, CDCl₃) 11.3, 11.8, 12.2, 19.7 (2C), 20.8, 21.0, 22.6, 22.7, 23.8, 24.4, 24.8, 28.0, 31.5, 32.7, 32.9, 37.3, 37.4 (2C), 37.5, 39.4, 39.8, 74.5, 117.3, 118.4, 121.0, 122.6, 144.5, 145.5. HRMS(ESI) calcd for C₂₉H₅₀O₂ (M⁺): 430.3811; found: 430.3801.



1-[2,4-Bis(benzyloxy)phenyl]ethan-1-one (S9).⁶ To a stirred solution of 2,4-dihydroxyacetophenone (**S8**, 5.00 g, 32.9 mmol) in MeCN (100 cm³) were added K₂CO₃ (13.6 g, 98.7 mmol) and


BnBr (8.59 cm³, 72.3 mmol). The mixture was stirred under reflux. After the mixture was stirred overnight, the reaction mixture was filtrated through Celite. After concentration, the residue was dissolved in Et₂O. The whole was washed with H₂O and brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure. Recrystallization from CHCl₃/hexane gave the title compound **S9** as colorless crystals (9.5 g, 90%): mp 75–77 °C (from CHCl₃/hexane); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 1661 (C=O); δ_{H} (500 MHz, CDCl₃) 2.55 (3H, s, CH₃), 5.09 (2H, s, CH₂), 5.11 (2H, s, CH₂), 6.60–6.63 (2H, m, Ar), 7.34–7.44 (10H, m, Ar), 7.85 (1H, dd, J_1 7.7, J_2 1.4, Ar); δ_{C} (125 MHz, CDCl₃) 32.2, 70.2, 70.7, 100.3, 106.2, 121.7, 127.5 (2C), 127.6 (2C), 128.3 (2C), 128.7 (4C), 132.7, 136.0, 136.1, 160.1, 163.5, 197.8. *Anal.* calcd. for C₂₂H₂₀O₃: C, 79.50; H, 6.07. Found: C, 79.56; H, 6.13.

1-[2,4-Bis(benzyloxy)phenyl]-2-bromoethan-1-one (11).⁷ A solution of phenyltrimethylammonium tribromide (PTT; 4.51 g, 12.0 mmol) in THF (14.6 cm³) was slowly added to compound **S9** (4.00 g, 12.0 mmol) at 0 °C. After the mixture was stirred for 2.5 h at room temperature, the reaction was quenched with H₂O. The whole was extracted with Et₂O and the extract was washed with H₂O and brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure. Recrystallization from CHCl₃/hexane gave the title compound **11** as pink crystals (3.98 g, 80%): mp 78–80 °C (from CHCl₃/hexane); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 1671 (C=O); δ_{H} (500 MHz, CDCl₃) 4.50 (2H, s, CH₂), 5.09 (2H, s, CH₂), 5.13 (2H, s, CH₂), 6.61 (1H, d, J 2.3, Ar), 6.65 (1H, dd, J_1 8.6, J_2 2.3, Ar), 7.34–7.45 (10H, m, Ar), 7.91 (1H, d, J 8.6, Ar); δ_{C} (125 MHz, CDCl₃) 37.8, 70.4, 71.1, 100.1, 107.0, 118.3, 127.5 (2C), 127.8 (2C), 128.4, 128.6, 128.7 (2C), 128.9 (2C), 133.9, 135.4, 135.9, 160.0, 164.3. *Anal.* calcd. for C₂₂H₁₉BrO₃: C, 64.25; H, 4.66. Found: C, 64.32; H, 4.75.




1-(2,4-Dihydroxyphenyl)-2-[(S)-2,5,7,8-tetramethyl-2-((4S,8S)-4,8,12-trimethyltridecyl)-chroman-6-yl]oxyethan-1-one (12b). To a stirred solution of compound **10b** (600 mg, 1.39 mmol) in DMF (1.4 cm³) were added K₂CO₃ (385 mg, 2.78 mmol) and compound **11** (745 mg, 1.81 mmol) at room temperature. After the mixture was stirred overnight, the reaction was quenched with H₂O. The whole was extracted with Et₂O and the extract was washed with H₂O and brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure. To a stirred solution of the residue in EtOAc (15.0 cm³) was added 10% Pd/C (149 mg, 0.140 mmol). The mixture was stirred under an atmosphere of H₂ at room temperature. After the reaction was completed, the reaction mixture was filtrated through Celite. Purification by column chromatography gave the title compound **12b** as pale yellow solid (583 mg, 72%): mp 87–88 °C (from EtOAc/hexane); $[\alpha]^{25}_{\text{D}} -4.0$ (*c* 1.01, CHCl₃); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 3315 (OH), 1627 (C=O); δ_{H} (500 MHz, CDCl₃) 0.84–0.87 (12H, m, 4CH₃), 1.04–1.57 (21H, m), 1.24 (3H, s, CH₃), 1.73–1.85 (2H, m, CH₂), 2.09 (3H, s, CH₃), 2.14 (3H, s, CH₃), 2.18 (3H, s, CH₃), 2.58 (2H, t, J 6.6, CH₂), 4.92 (2H, s, CH₂), 5.80 (1H, br s, OH), 6.36 (1H, dd, J_1 8.6, J_2 2.3 Hz, Ar), 6.42 (1H, d, J 2.3, Ar), 7.52 (1H, d, J 7.7, Ar), 12.40 (1H, s, OH); δ_{C} (125 MHz, CDCl₃) 11.8, 11.9, 12.8, 19.7 (2C), 20.6, 21.0, 22.6, 22.7, 23.8, 24.4, 24.8, 28.0, 31.2, 32.7, 32.8, 37.3, 37.4 (3C), 39.4, 40.0, 74.0, 75.0,

103.8, 108.0, 111.9, 117.8, 123.2, 125.7, 127.6, 130.9, 147.8, 148.3, 162.8, 165.3, 198.0. *Anal.* calcd. for C₃₇H₅₆O₅: C, 76.51; H, 9.72. Found: C, 76.41; H, 9.89.



1-(2,4-Dihydroxyphenyl)-2-[(R)-2,5,7,8-tetramethyl-2-((4S,8S)-4,8,12-trimethyltridecyl)chroman-6-yl]oxyethan-1-one (12c). According to the procedure described for the preparation of **12b**, compound **10c** (100 mg, 0.232 mmol) was converted into compound **12c** as pale yellow solid (88.9 mg, 66%): mp 86–87 °C (from EtOAc/hexane); [α]²⁵_D +3.7 (*c* 0.55, CHCl₃); IR (neat) ν_{max} /cm⁻¹: 3351 (OH), 1626 (C=O); δ_H(500 MHz, CDCl₃) 0.84–0.87 (12H, m, 4CH₃), 1.04–1.61 (21H, m), 1.24 (3H, s, CH₃), 1.73–1.85 (2H, m, CH₂), 2.08 (3H, s, CH₃), 2.14 (3H, s, CH₃), 2.18 (3H, s, CH₃), 2.58 (2H, t, *J* 6.6, CH₂), 4.92 (2H, s, CH₂), 6.36 (1H, dd, *J*₁ 8.9, *J*₂ 2.6, Ar), 6.42 (1H, d, *J* 2.3, Ar), 7.51 (1H, d, *J* 7.7, Ar), 12.40 (1H, s, OH); δ_C(125 MHz, CDCl₃) 11.8, 11.9, 12.8, 19.7 (2C), 20.6, 21.0, 22.6, 22.7, 23.8, 24.4, 24.8, 28.0, 31.1, 32.7, 32.8, 37.3, 37.4 (2C), 37.5, 39.4, 40.1, 74.0, 75.0, 103.8, 108.1, 111.9, 117.8, 123.2, 125.7, 127.6, 130.9, 147.8, 148.3, 162.9, 165.3, 198.0. *Anal.* calcd. for C₃₇H₅₆O₅: C, 76.51; H, 9.72. Found: C, 76.35; H, 9.79.



1-(2,4-Dihydroxyphenyl)-2-[(S)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-yl]oxyethan-1-one (12d). According to the procedure described for the preparation of **12b**, compound **10d** (500 mg, 1.16 mmol) was converted into compound **12d** as pale yellow solid (483 mg, 72%): mp 86–87 °C (from EtOAc/hexane); [α]²⁵_D -3.9 (*c* 1.11, CHCl₃); IR (neat) ν_{max} /cm⁻¹: 3350 (OH), 1626 (C=O); δ_H(500 MHz, CDCl₃) 0.84–0.87 (12H, m, 4CH₃), 1.04–1.61 (21H, m), 1.24 (3H, s, CH₃), 1.73–1.85 (2H, m, CH₂), 2.08 (3H, s, CH₃), 2.14 (3H, s, CH₃), 2.18 (3H, s, CH₃), 2.58 (2H, t, *J* 6.9, CH₂), 4.92 (2H, s, CH₂), 6.36 (1H, dd, *J*₁ 8.9, *J*₂ 2.6, Ar), 6.42 (1H, d, *J* 2.9, Ar), 7.51 (1H, d, *J* 9.2, Ar), 12.40 (1H, s, OH); δ_C(125 MHz, CDCl₃) 11.8, 11.9, 12.8, 19.7 (2C), 20.6, 21.0, 22.6, 22.7, 23.8, 24.4, 24.8, 28.0, 31.1, 32.7, 32.8, 37.3, 37.4 (2C), 37.5, 39.4, 40.1, 74.0, 75.0, 103.8, 108.1, 111.8, 117.8, 123.2, 125.7, 127.6, 130.9, 147.7, 148.3, 163.0, 165.3, 198.0. HRMS (ESI) calcd for C₃₇H₅₇O₅ (MH⁺): 581.4201; found: 581.4207.

7-Hydroxy-3-[(S)-2,5,7,8-tetramethyl-2-((4S,8S)-4,8,12-trimethyltridecyl)chroman-6-yl]oxy-4*H*-chromen-4-one (1b: *ent*-NP843). To a stirred solution of compound **12b** (100 mg, 0.172 mmol) in THF (0.76 cm³) was added DMF-DMA (0.0277 cm³, 0.260 mmol) under argon, and the mixture was stirred under reflux for 4 h. Then, aqueous 1*N* HCl (1 cm³) and MeOH (1 cm³) were added and the mixture was stirred overnight. The whole was extracted with Et₂O and dried over Na₂SO₄. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography to give the title compound **1b** as white solid (23.3 mg, 23%): mp 228–229 °C (from


EtOAc); $[\alpha]^{25}_{\text{D}} -5.3$ (*c* 1.00, CHCl₃); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 3133 (OH); δ_{H} (500 MHz, CDCl₃) 0.84-0.87 (12H, m, 4CH₃), 1.03-1.59 (21H, m), 1.25 (3H, s, CH₃), 1.75-1.85 (2H, m, CH₂), 2.02 (3H, s, CH₃), 2.06 (3H, s, CH₃), 2.09 (3H, s, CH₃), 2.58 (2H, t, *J* 6.9, CH₂), 6.86 (1H, d, *J* 2.3, Ar), 7.07-7.10 (2H, m, Ar), 8.22 (1H, d, *J* 9.2, Ar), 8.55 (1H, br s, OH); δ_{C} (125 MHz, CDCl₃) 11.8 (2C), 12.6, 19.6, 19.7, 20.6, 21.0, 22.6, 22.7, 23.8, 24.4, 24.8, 28.0, 31.2, 32.7, 32.8, 37.3, 37.4 (3C), 39.4, 40.0, 75.2, 102.7, 115.5, 117.0, 118.2, 123.7, 125.3, 127.1, 127.6, 140.0, 142.8, 143.4, 149.0, 157.8, 162.1, 172.6. *Anal.* calcd. for C₃₈H₅₄O₅: C, 77.25; H, 9.21. Found: C, 77.22; H, 9.43.

7-Hydroxy-3-{|(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-yl|oxy}-4H-chromen-4-one (1a, NP843). mp 228–229 °C (from EtOAc); $[\alpha]^{25}_{\text{D}} +5.0$ (*c* 1.00, CHCl₃); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 3163 (OH); δ_{H} (500 MHz, CDCl₃) 0.84-0.87 (12H, m, 4CH₃), 1.03-1.59 (21H, m), 1.25 (3H, s, CH₃), 1.75-1.85 (2H, m, CH₂), 2.02 (3H, s, CH₃), 2.06 (3H, s, CH₃), 2.09 (3H, s, CH₃), 2.58 (2H, t, *J* 6.9, CH₂), 6.86 (1H, d, *J* 2.3, Ar), 7.07-7.10 (2H, m, Ar), 8.22 (1H, d, *J* 9.2, Ar), 8.67 (1H, br s, OH); δ_{C} (125 MHz, CDCl₃) 11.8 (2C), 12.6, 19.6, 19.7, 20.6, 21.0, 22.6, 22.7, 23.7, 24.4, 24.8, 28.0, 31.2, 32.7, 32.8, 37.3, 37.4 (3C), 39.4, 40.0, 75.3, 102.7, 115.5, 117.0, 118.2, 123.7, 125.3, 127.1, 127.6, 140.0, 142.8, 143.4, 149.0, 157.8, 162.2, 172.6. *Anal.* calcd. for C₃₈H₅₄O₅: C, 77.25; H, 9.21. Found: C, 77.13; H, 9.40.

7-Hydroxy-3-{|(R)-2,5,7,8-tetramethyl-2-((4S,8S)-4,8,12-trimethyltridecyl)chroman-6-yl|oxy}-4H-chromen-4-one (1c). According to the procedure described for the preparation of **1b**, compound **12c** (50.0 mg, 0.0861 mmol) was converted into compound **1c** as white solid (12.2 mg, 24%): mp 229–231 °C (from EtOAc); $[\alpha]^{25}_{\text{D}} +5.4$ (*c* 1.01, CHCl₃); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 3125 (OH); δ_{H} (500 MHz, CDCl₃) 0.84-0.87 (12H, m, 4CH₃), 1.03-1.64 (21H, m), 1.25 (3H, s, CH₃), 1.75-1.85 (2H, m, CH₂), 2.02 (3H, s, CH₃), 2.06 (3H, s, CH₃), 2.09 (3H, s, CH₃), 2.58 (2H, t, *J* 6.9, CH₂), 6.86 (1H, d, *J* 2.3, Ar), 7.07-7.10 (2H, m, Ar), 8.22 (1H, d, *J* 9.2, Ar), 8.57 (1H, br s, OH); δ_{C} (125 MHz, CDCl₃) 11.8 (2C), 12.6, 19.7 (2C), 20.6, 21.0, 22.6, 22.7, 23.7, 24.4, 24.8, 28.0, 31.1, 32.7, 32.8, 37.3, 37.4 (3C), 39.4, 40.0, 75.3, 102.7, 115.5, 117.0, 118.3, 123.7, 125.3, 127.1, 127.6, 140.0, 142.8, 143.4, 149.1, 157.8, 162.1, 172.6. *Anal.* calcd. for C₃₈H₅₄O₅·0.15EtOAc: C, 76.75; H, 9.21. Found: C, 76.40; H, 9.21.


7-Hydroxy-3-{|(S)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-yl|oxy}-4H-chromen-4-one (1d). According to the procedure described for the preparation of **1b**, compound **12d** (100 mg, 0.172 mmol) was converted into compound **1d** as white solid (23.5 mg, 23%): mp 229–231 °C (from EtOAc); $[\alpha]^{25}_{\text{D}} -5.4$ (*c* 0.95, CHCl₃); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 3126 (OH); δ_{H} (500 MHz, CDCl₃) 0.84-0.87 (12H, m, 4CH₃), 1.03-1.64 (21H, m), 1.25 (3H, s, CH₃), 1.75-1.85 (2H, m, CH₂), 2.02 (3H, s, CH₃), 2.06 (3H, s, CH₃), 2.09 (3H, s, CH₃), 2.58 (2H, t, *J* 6.9, CH₂), 6.86 (1H, d, *J* 2.3, Ar), 7.07-7.10 (2H, m, Ar), 8.22 (1H, d, *J* 9.2, Ar), 8.51 (1H, br s, OH); δ_{C} (125 MHz, CDCl₃) 11.8 (2C), 12.6, 19.7 (2C), 20.6, 21.0, 22.6, 22.7, 23.8, 24.4, 24.8, 28.0, 31.1, 32.7, 32.8, 37.3, 37.4 (3C), 39.4, 40.0, 75.3, 102.7, 115.4, 117.0, 118.3, 123.7, 125.3, 127.1, 127.6, 139.9, 142.8, 143.4, 149.1, 157.8, 162.1, 172.6. *Anal.* calcd. for C₃₈H₅₄O₅: C, 77.25; H, 9.21. Found: C, 77.36; H, 9.32.

Synthesis of Compounds 13a,b



(S)-(3,7-Dimethyloct-6-en-1-yl)triphenylphosphonium Bromide (S10). According to the procedure described for the preparation of **8**, (*S*)-citronellyl bromide (3.99 g, 18.2 mmol) was converted into compound **S10**, which was used without further purification.


(R)-2-((*S*)-4,8-Dimethylnonyl)-2,5,7,8-tetramethylchroman-6-ol (S11a). According to the procedure described for the preparation of **10b**, compound *ent*-**9** (800 mg, 2.47 mmol) was converted into compound **S11a** using the phosphonium salt **S10** (ca. 4.93 mmol) as a pale yellow oil (735 mg, 83%). $[\alpha]^{25}_{\text{D}} +0.4$ (*c* 1.00, CHCl_3); δ_{H} (500 MHz, CDCl_3) 0.83-0.88 (9H, m, 3CH_3), 1.05-1.53 (14H, m), 1.23 (3H, s, CH_3), 1.73-1.84 (2H, m, CH_2), 2.11 (6H, s, 2CH_3), 2.16 (3H, s, CH_3), 2.60 (2H, t, *J* 6.9, CH_2), 4.18 (1H, s, OH); δ_{C} (125 MHz, CDCl_3) 11.3, 11.8, 12.2, 19.7 (2C), 21.0, 22.6, 22.7, 23.8, 24.7, 28.0, 31.5, 32.7, 37.2, 37.5, 39.3, 39.8, 74.5, 117.3, 118.4, 121.0, 122.6, 144.5, 145.5. HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{40}\text{O}_2$ (M^+): 360.3028; found: 360.3026.



(S)-2-((*S*)-4,8-Dimethylnonyl)-2,5,7,8-tetramethylchroman-6-ol (S11b). According to the procedure described for the preparation of **10b**, compound **9** (800 mg, 2.47 mmol) was converted into compound **S11b** using phosphonium salt **S10** (ca. 4.93 mmol) as a pale yellow oil (730 mg, 82%). $[\alpha]^{25}_{\text{D}} +1.5$ (*c* 1.00, CHCl_3); δ_{H} (500 MHz, CDCl_3) 0.83-0.88 (m, 9H), 1.04-1.53 (m, 14H), 1.23 (s, 3H), 1.73-1.84 (m, 2H), 2.11 (s, 6H), 2.16 (s, 3H), 2.60 (t, *J* = 6.9 Hz, 2H), 4.18 (s, 1H); δ_{C} (125 MHz, CDCl_3) 11.3, 11.8, 12.2, 19.6, 20.7, 21.0, 22.6, 22.7, 23.8, 24.8, 28.0, 31.5, 32.7, 37.3, 37.5, 39.3, 39.7, 74.5, 117.3, 118.4, 121.0, 122.6, 144.5, 145.5. HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{40}\text{O}_2$ (M^+): 360.3028; found: 360.3035.

1-(2,4-Dihydroxyphenyl)-2-[(*R*)-2-((*S*)-4,8-dimethylnonyl)-2,5,7,8-tetramethylchroman-6-yl]-oxy}ethan-1-one (S12a). According to the procedure described for the preparation of **12b**, compound **S11a** (700 mg, 1.94 mmol) was converted into compound **S12a** as a pale yellow solid (916 mg, 84%): mp 89–91 °C (from EtOAc/hexane); $[\alpha]^{25}_{\text{D}} +3.8$ (*c* 0.70, CHCl_3); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 3341 (OH), 1626 (C=O); δ_{H} (500 MHz, CDCl_3) 0.84-0.87 (9H, m, 3CH_3), 1.06-1.61 (14H, m), 1.24 (3H, s, CH_3), 1.73-1.85 (2H, m, CH_2), 2.09 (3H, s, CH_3), 2.14 (3H, s, CH_3), 2.18 (3H, s, CH_3), 2.57 (2H, t, *J* 6.6, CH_2), 4.93 (2H, s, CH_2), 6.37 (1H, dd, *J*₁ 8.9, *J*₂ 2.6, Ar), 6.42 (1H, d, *J* 2.9, Ar), 7.49 (1H, d, *J* 8.6, Ar), 12.37 (1H, s, OH); δ_{C} (125 MHz, CDCl_3) 11.8, 11.9, 12.8, 19.6, 20.6, 21.0, 22.6, 22.7, 23.8, 24.7, 28.0,

31.1, 32.7, 37.2, 37.5, 39.3, 40.0, 73.9, 75.0, 103.8, 108.2, 111.7, 117.8, 123.2, 125.7, 127.6, 130.8, 147.7, 148.3, 163.2, 165.3, 198.0. HRMS (ESI) calcd for C₃₂H₄₇O₅ (MH⁺): 511.3418; found: 511.3414.




1-(2,4-Dihydroxyphenyl)-2-{[(S)-2-((S)-4,8-dimethylnonyl)-2,5,7,8-tetramethylchroman-6-yl]oxy}ethan-1-one (S12b). According to the procedure described for the preparation of **12b**, compound **S11b** (700 mg, 1.94 mmol) was converted into compound **S12b** as a pale yellow solid (766 mg, 79%): mp 89–91 °C (from EtOAc/hexane); [α]²⁵_D –3.7 (*c* 0.62, CHCl₃); IR (neat) ν_{max}/cm^{–1}: 3363 (OH), 1626 (C=O); δ_H(500 MHz, CDCl₃) 0.84–0.87 (9H, m, 3CH₃), 1.03–1.60 (14H, m), 1.24 (3H, s, CH₃), 1.73–1.85 (2H, m, CH₂), 2.09 (3H, s, CH₃), 2.14 (3H, s, CH₃), 2.18 (3H, s, CH₃), 2.57 (2H, t, *J* 6.6, CH₂), 4.93 (2H, s, CH₂), 6.26 (s, 1H), 6.37 (1H, dd, *J*₁ 9.2, *J*₂ 2.3, Ar), 6.42 (1H, d, *J* 2.9, Ar), 7.50 (1H, d, *J* 9.2, Ar), 12.38 (1H, s, OH); δ_C(125 MHz, CDCl₃) 11.8, 11.9, 12.8, 19.6, 20.6, 21.0, 22.6, 22.7, 23.8, 24.7, 28.0, 31.2, 32.7, 37.3, 37.5, 39.3, 40.0, 73.9, 75.0, 103.8, 108.2, 111.7, 117.8, 123.2, 125.7, 127.6, 130.9, 147.7, 148.3, 163.1, 165.3, 198.0. HRMS (ESI) calcd for C₃₂H₄₇O₅ (MH⁺): 511.3418; found: 511.3419.

3-{[(R)-2-((S)-4,8-Dimethylnonyl)-2,5,7,8-tetramethylchroman-6-yl]oxy}-7-hydroxy-4*H*-chromen-4-one (13a). According to the procedure described for the preparation of **1b**, compound **S12a** (100 mg, 0.196 mmol) was converted into compound **13a** as a white solid (20.5 mg, 20%): mp 239–241 °C (from EtOAc); [α]²⁵_D +5.4 (*c* 0.33, CHCl₃); IR (neat) ν_{max}/cm^{–1}: 3116 (OH); δ_H(500 MHz, CDCl₃) 0.84–0.87 (9H, m, 3CH₃), 1.06–1.61 (14H, m), 1.25 (3H, s, CH₃), 1.75–1.85 (2H, m, CH₂), 2.02 (3H, s, CH₃), 2.05 (3H, s, CH₃), 2.09 (3H, s, CH₃), 2.58 (2H, t, *J* 6.7, CH₂), 6.86 (1H, d, *J* 2.3, Ar), 7.07–7.10 (2H, m, Ar), 8.22 (1H, d, *J* 8.7, Ar), 8.59 (1H, br s, OH); δ_C(125 MHz, CDCl₃) 11.8 (2C), 12.7, 19.6, 20.6, 21.0, 22.6, 22.7, 23.8, 24.7, 28.0, 31.1, 32.7, 37.2, 37.5, 39.3, 39.9, 75.3, 102.7, 115.5, 117.0, 118.3, 123.7, 125.3, 127.1, 127.6, 140.0, 142.8, 143.4, 149.0, 157.8, 162.1, 172.6. *Anal.* calcd. for C₃₃H₄₄O₅·0.25EtOAc: C, 75.24; H, 8.54. Found: C, 75.08; H, 8.60.


3-{[(S)-2-((S)-4,8-Dimethylnonyl)-2,5,7,8-tetramethylchroman-6-yl]oxy}-7-hydroxy-4*H*-chromen-4-one (13b). According to the procedure described for the preparation of **1b**, compound **S12b** (100 mg, 0.196 mmol) was converted into compound **13b** as a white solid (23.4 mg, 23%): mp 239–241 °C (from EtOAc); [α]²⁵_D –5.6 (*c* 0.39, CHCl₃); IR (neat) ν_{max}/cm^{–1}: 3131 (OH); δ_H(500 MHz, CDCl₃) 0.86 (9H, d, *J* 6.3, 3CH₃), 1.05–1.59 (14H, m), 1.25 (3H, s, CH₃), 1.76–1.84 (2H, m, CH₂), 2.02 (3H, s, CH₃), 2.06 (3H, s, CH₃), 2.09 (3H, s, CH₃), 2.58 (2H, t, *J* 6.9, CH₂), 6.85 (1H, d, *J* 1.7, Ar), 7.07 (1H, dd, *J*₁ 9.2, *J*₂ 2.3, Ar), 7.09 (1H, s, Ar), 8.22 (1H, d, *J* 8.6, Ar), 8.38 (1H, br s, OH); δ_C(125 MHz, CDCl₃) 11.8 (2C), 12.6, 19.6, 20.6, 21.0, 22.6, 22.7, 23.7, 24.7, 28.0, 31.2, 32.7, 37.3, 37.5, 39.3, 39.9, 75.3, 102.7, 115.7, 116.7, 118.3, 123.6, 125.3, 127.1, 127.4, 140.2, 142.8, 143.3, 149.0, 157.9, 162.5, 172.7. *Anal.* calcd. for C₃₃H₄₄O₅·0.1EtOAc: C, 75.76; H, 8.53. Found: C, 75.65; H, 8.58.

Synthesis of Compounds 14a,b




(Isopentyl)triphenylphosphonium Bromide (S14). According to the procedure described for the preparation of **8**, 1-bromo-3-methylbutane (**S13**, 1.99 g, 13.2 mmol) was converted into compound **S14**, which was used without further purification.

(R)-2,5,7,8-Tetramethyl-2-(4-methylpentyl)chroman-6-ol (S15a). According to the procedure described for the preparation of **10b**, compound *ent*-**9** (800 mg, 2.47 mmol) was converted into compound **S15a** using the phosphonium salt **S14** (ca. 4.93 mmol) as a pale yellow oil (675 mg, 94%). $[\alpha]^{25}_{\text{D}} -0.9$ (*c* 1.00, CHCl_3); δ_{H} (500 MHz, CDCl_3) 0.87 (6H, d, *J* 6.9, 2 CH_3), 1.14-1.19 (2H, m), 1.22 (3H, s, CH_3), 1.37-1.58 (5H, m), 1.73-1.84 (2H, m, CH_2), 2.11 (6H, s, 2 CH_3), 2.16 (3H, s, CH_3), 2.60 (2H, t, *J* 6.9, CH_2), 4.17 (1H, s, OH); δ_{C} (125 MHz, CDCl_3) 11.3, 11.8, 12.2, 20.7, 21.4, 22.6 (2C), 23.8, 27.9, 31.5, 39.4, 39.7, 74.5, 117.3, 118.4, 121.0, 122.6, 144.5, 145.5. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{30}\text{O}_2$ (M^+): 290.2246; found: 290.2245.



(S)-2,5,7,8-Tetramethyl-2-(4-methylpentyl)chroman-6-ol (S15b). According to the procedure described for the preparation of **10b**, compound **9** (800 mg, 2.47 mmol) was converted into compound **S15b** using compound **S14** (ca. 4.93 mmol) as a pale yellow oil (621 mg, 86%). $[\alpha]^{25}_{\text{D}} +0.9$ (*c* 1.00, CHCl_3); δ_{H} (500 MHz, CDCl_3) 0.87 (6H, d, *J* 6.9, 2 CH_3), 1.14-1.19 (2H, m), 1.22 (3H, s, CH_3), 1.37-1.58 (5H, m), 1.73-1.84 (2H, m, CH_2), 2.11 (6H, s, 2 CH_3), 2.16 (3H, s, CH_3), 2.60 (2H, t, *J* 6.9, CH_2), 4.17 (1H, s, OH); δ_{C} (125 MHz, CDCl_3) 11.3, 11.8, 12.2, 20.7, 21.4, 22.6 (2C), 23.8, 27.9, 31.5, 39.4, 39.7, 74.5, 117.3, 118.4, 121.0, 122.6, 144.5, 145.5. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{30}\text{O}_2$ (M^+): 290.2246; found: 290.2239.

(R)-1-(2,4-Dihydroxyphenyl)-2-[2,5,7,8-tetramethyl-2-(4-methylpentyl)chroman-6-yl]ethan-1-one (S16a). According to the procedure described for the preparation of **12b**, compound **S15a** (600 mg, 2.07 mmol) was converted into compound **S16a** as a pale yellow solid (765 mg, 84%): mp 86–87 °C (from $\text{EtOAc}/\text{hexane}$); $[\alpha]^{25}_{\text{D}} +3.5$ (*c* 0.78, CHCl_3); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 3351 (OH), 1626 (C=O); δ_{H} (500 MHz, CDCl_3) 0.87 (6H, d, *J* 6.9, 2 CH_3), 1.18 (2H, dd, *J*₁ 14.9, *J*₂ 6.9, CH_2), 1.24 (3H, s, CH_3), 1.37-1.61 (5H, m), 1.73-1.85 (2H, m, CH_2), 2.08 (3H, s, CH_3), 2.14 (3H, s, CH_3), 2.18 (3H, s, CH_3), 2.57 (2H, t, *J* 6.6, CH_2), 4.93 (2H, s, CH_2), 6.36 (1H, dd, *J*₁ 8.9, *J*₂ 2.3, Ar), 6.42 (1H, d, *J* 2.3, Ar), 6.52 (1H, br s, OH), 7.49 (1H, d, *J* 9.2 Hz, Ar), 12.37 (1H, s, OH); δ_{C} (125 MHz, CDCl_3) 11.8, 11.9, 12.8, 20.6, 21.3, 22.6 (2C), 23.8, 27.8, 31.1, 39.3, 39.9, 73.9, 75.0, 103.8, 108.1, 111.7, 117.8, 123.2, 125.7, 127.6, 130.8, 147.7, 148.3, 163.3, 165.3, 198.0. HRMS (ESI) calcd for $\text{C}_{27}\text{H}_{37}\text{O}_5$ (MH^+): 441.2636; found: 441.2633.



(S)-1-(2,4-Dihydroxyphenyl)-2-{[2,5,7,8-tetramethyl-2-(4-methylpentyl)chroman-6-yl]oxy}ethan-1-one (S16b). According to the procedure described for the preparation of **12b**, compound **S15b** (600 mg, 2.07 mmol) was converted into compound **S16b** as pale yellow solid (505 mg, 55%): mp 86–87 °C (from EtOAc/hexane); $[\alpha]^{25}_D -3.9$ (*c* 1.11, CHCl₃); IR (neat) $\nu_{\max}/\text{cm}^{-1}$: 3351 (OH), 1626 (C=O); δ_{H} (500 MHz, CDCl₃) 0.87 (6H, d, *J* 6.9, 2CH₃), 1.17 (2H, dd, *J*₁ 14.9, *J*₂ 6.9, CH₂), 1.24 (3H, s, CH₃), 1.37–1.61 (5H, m), 1.73–1.85 (2H, m, CH₂), 2.09 (3H, s, CH₃), 2.14 (3H, s, CH₃), 2.18 (3H, s, CH₃), 2.57 (2H, t, *J* 6.6, CH₂), 4.93 (2H, s, CH₂), 6.28 (1H, br s, OH), 6.37 (1H, dd, *J*₁ 8.9, *J*₂ 2.3, Ar), 6.42 (1H, d, *J* 2.3, Ar), 7.50 (1H, d, *J* 9.2 Hz, Ar), 12.38 (1H, s, OH); δ_{C} (125 MHz, CDCl₃) 11.8, 11.9, 12.8, 20.6, 21.3, 22.6 (2C), 23.8, 27.8, 31.1, 39.3, 39.9, 73.9, 75.0, 103.8, 108.1, 111.7, 117.8, 123.2, 125.7, 127.6, 130.8, 147.7, 148.3, 163.1, 165.3, 198.0. *Anal.* calcd. for C₂₇H₃₆O₅: C, 73.61; H, 8.24. Found: C, 73.39; H, 8.49.

(R)-7-Hydroxy-3-{[2,5,7,8-tetramethyl-2-(4-methylpentyl)chroman-6-yl]oxy}-4*H*-chromen-4-one (14a). According to the procedure described for the preparation of **1b**, compound **S16a** (100 mg, 0.227 mmol) was converted into compound **14a** as white solid (23.0 mg, 23%): mp 255–258 °C (from EtOAc); $[\alpha]^{25}_D +5.3$ (*c* 0.40, THF); IR (neat) $\nu_{\max}/\text{cm}^{-1}$: 3265 (OH); δ_{H} (500 MHz, THF-*d*₈) 2.69 (3H, d, *J* 2.9, CH₃), 2.70 (3H, d, *J* 2.9, CH₃), 3.01 (2H, dd, *J*₁ 14.9, *J*₂ 6.9, CH₂), 3.06 (3H, s, CH₃), 3.26–3.43 (5H, m), 3.56–3.68 (2H, m, CH₂), 3.82 (3H, s, CH₃), 3.86 (3H, s, CH₃), 3.89 (3H, s, CH₃), 4.44 (2H, t, *J* 6.9, CH₂), 8.47 (1H, d, *J* 2.3, Ar), 8.64 (1H, dd, *J*₁ 8.6, *J*₁ 2.3, Ar), 8.84 (1H, s, Ar), 9.87 (1H, d, *J* 8.6, Ar), 11.19 (1H, s, OH); δ_{C} (125 MHz, THF-*d*₈) 10.9, 11.1, 11.8, 20.4, 21.4, 22.0 (2C), 23.2, 27.9, 31.1, 39.5, 39.9, 74.9, 101.9, 114.1, 117.5, 118.0, 123.2, 125.2, 126.9, 127.3, 139.2, 143.4, 143.8, 148.9, 157.6, 162.4, 170.0. *Anal.* calcd. for C₂₈H₃₄O₅·0.1EtOAc: C, 74.25; H, 7.64. Found: C, 74.12; H, 7.61.

(S)-7-Hydroxy-3-{[2,5,7,8-tetramethyl-2-(4-methylpentyl)chroman-6-yl]oxy}-4*H*-chromen-4-one (14b). According to the procedure described for the preparation of **1b**, compound **S16b** (100 mg, 0.227 mmol) was converted into compound **14b** as white solid (22.7 mg, 22%): mp 255–258 °C (from EtOAc); $[\alpha]^{25}_D -5.1$ (*c* 0.52, THF); IR (neat) $\nu_{\max}/\text{cm}^{-1}$: 3147 (OH); δ_{H} (500 MHz, THF-*d*₈) 2.69 (3H, d, *J* 2.9, CH₃), 2.70 (3H, d, *J* 2.9, CH₃), 3.01 (2H, dd, *J*₁ 14.9, *J*₂ 6.9, CH₂), 3.06 (3H, s, CH₃), 3.26–3.43 (5H, m), 3.56–3.68 (2H, m, CH₂), 3.82 (3H, s, CH₃), 3.86 (3H, s, CH₃), 3.89 (3H, s, CH₃), 4.44 (2H, t, *J* 6.9, CH₂), 8.47 (1H, d, *J* 2.3, Ar), 8.64 (1H, dd, *J*₁ 8.6, *J*₁ 2.3, Ar), 8.84 (1H, s, Ar), 9.87 (1H, d, *J* 8.6, Ar), 11.20 (1H, s, OH); δ_{C} (125 MHz, THF-*d*₈) 10.9, 11.1, 11.8, 20.4, 21.4, 22.0 (2C), 23.2, 27.9, 31.1, 39.5, 39.9, 74.9, 101.9, 114.1, 117.5, 118.0, 123.2, 125.2, 126.9, 127.3, 139.2, 143.3, 143.8, 148.9, 157.6, 162.4, 170.0. *Anal.* calcd. for C₂₈H₃₄O₅: C, 74.64; H, 7.61. Found: C, 74.33; H, 7.74.

Screening by the Chemical Array

Photoaffinity linker-coated (PALC) slides were prepared according to previous reports using amine-coated slides and the photoaffinity proline linker.⁸⁻¹⁰ A solution of compounds (2.5 mg cm⁻³ in DMSO) from the in-house chemical library (NPDepo, RIKEN) was immobilized onto the PALC glass slides with a chemical arrayer equipped with 24 stamping pins. The slides were exposed to UV irradiation of 4 J cm⁻² at 365 nm using a CL-1000L UV crosslinker (UVP, CA). The slides were washed successively with DMSO, DMF, acetonitrile, THF, dichloromethane, EtOH, and ultra-pure water (5 min, 3 times each), and dried. D- or L-MDM2^{TMR} (3 μmol dm⁻³ in 1% skim-milk-TBS-T) was incubated with the glass slide for 1 h, and then washed with TBS-T (10 mmol dm⁻³ Tris-HCl (pH 8.0), 150 mmol dm⁻³ NaCl, 0.05% Tween-20) (5 min, 3 times). The slides were dried and scanned at 532 nm on a GenePix scanner. The fluorescence signals were quantified with GenePixPro (Table S1).

Fluorescent Polarization Assay

Fluorescence polarization (FP) assays were carried out in PBS containing 2% DMSO and 0.005% Tween-20 using a fluorescein-labeled p53 (P4) peptide (0.5-1.0 nmol dm⁻³) and MDM2²⁵⁻¹⁰⁹ (10 nmol dm⁻³) in black 96-well non-binding surface assay plates (Corning).¹ The potential inhibitors and fluorescein-labeled P4 peptide in DMSO were diluted five-fold with PBS in advance. The protein (0.090 cm³) was preincubated with the compound solution (0.005 cm³) for 30 min. Then, the fluorescein-labeled P4 peptide (0.005 cm³) was added and incubated for 30 min. The P4 peptide was used as the positive control. FP signals were analyzed using an EnVision Xcite plate reader (Perkin Elmer) with a 480-nm excitation filter and a 535-nm emission filter. The mP values of the assay were calculated according to the report by Czarna *et al* (Table 1, Table S2, Figure S6).¹¹

SPR Analysis

SPR Analyses of p53 binding to synthetic MDM2²⁵⁻¹⁰⁹ and MDM2^{TMR} were carried out using Biacore T200 SPR instrument. PBS (Nacalai Tesque, pH 7.4) containing 0.05 % Tween-20 was used as the running buffer at 25 °C. Biotinylated wild-type p53 peptides (biotinyl-aminocaproyl-GSGS-SQETFSSDLWKLLPEN-NH₂) were immobilized on a SA sensor chip (L-p53: 45.1 RU, D-p53: 46.4 RU). All analytes were evaluated for 2 min as contact time, followed by 2 min dissociation at a flow rate of 30 μL min⁻¹ (Figure S4).

For competitive inhibition assays, L-MDM2²⁵⁻¹⁰⁹ (30 nmol dm⁻³) in the presence of varying concentration of inhibitors in PBS containing 0.05% Tween-20 and 1% DMSO were injected on SA sensor chip, where biotinylated wild-type L-p53 peptide was immobilized (127.3 RU) (Table S3, Figure S6).

Competitive Binding Inhibition Assay by a Standard ELISA

ELISA assays were carried out in HEPES buffer [20 mmol dm⁻³ HEPES (pH7.4), 100 mmol dm⁻³ NaCl, 0.05% Tween-20, 0.1% BSA]. Precoated streptavidin 96-well plates (Nunc) were incubated with HEPES buffer containing 3% BSA (0.300 cm³ well⁻¹) for 1h. After three washes, biotinylated wild-type p53 peptide (100 nmol dm⁻³) in HEPES buffer (0.100 cm³ well⁻¹) was added and incubated for 2 h. After three washes, 100 nmol dm⁻³ MDM2 (recombinant human MDM2, untagged, Sigma) in

the presence of varying concentration of inhibitors in HEPES buffer containing 1% DMSO ($0.100 \text{ cm}^3 \text{ well}^{-1}$) was added and incubated for 1 h. After three washes, 1:1000 dilution of anti-MDM2 rabbit IgG antibody (N-20, Santa Cruz) in HEPES buffer ($0.100 \text{ cm}^3 \text{ well}^{-1}$) was added and incubated for 1 h. After three washes, 1:5000 dilution of HRP-conjugated anti-rabbit IgG antibody (Promega) in HEPES buffer ($0.100 \text{ cm}^3 \text{ well}^{-1}$) was added and incubated for 1 h. After three washes, TMB (3,3',5,5'-Tetramethylbenzidine) solution (WAKO, $0.100 \text{ cm}^3 \text{ well}^{-1}$) was added and incubated for 1 h. Then, aqueous 2 N H_2SO_4 ($0.010 \text{ cm}^3 \text{ well}^{-1}$) was added. Absorbance at 450 nm was measured for each well using an EnVision Xcite plate reader. The IC_{50} values were calculated by using GraphPad Prism (GraphPad software, San Diego, CA) (Table S3, Figure S6).


Cell Growth Inhibition Assay

SJSA-1 and H1299 cells were cultured in RPMI-1640 medium (high glucose) (WAKO) supplemented with 10% (v/v) FBS at 37°C in a 5% CO_2 -incubator. Cell-based assays using SJSA-1 and H1299 cells were performed in 96-well plates (BD Falcon). Both cells were seeded at 500 cells well^{-1} in 0.050 cm^3 of DMEM, and placed for 6 h. Chemical compounds in DMSO were diluted 250-fold with the culture medium in advance. Following the addition of the fresh culture medium (0.040 cm^3), the chemical diluents (0.030 cm^3) were also added to the cell cultures. The final volume of DMSO in the medium was equal to 0.1% (v/v). The cells under chemical treatment were incubated for a further 72 h. The wells in the plates were washed with the cultured medium without phenol-red twice. After 1 h of incubation with 0.10 cm^3 of the medium, the cell culture in each well was supplemented with the MTS reagent (0.020 cm^3 , Promega), followed by incubation for an additional 40 min. Absorbance at 490 nm was measured for each well using an EnVision Xcite plate reader. The GI_{50} values were calculated by using GraphPad Prism (GraphPad software, San Diego, CA) (Figure S8).

References

- 1 T. Noguchi, S. Oishi, K. Honda, Y. Kondoh, T. Saito, T. Kubo, M. Kaneda, H. Ohno, H. Osada and N. Fujii, *Bioorg. Med. Chem. Lett.* 2013, **23**, 3802.
- 2 M. Fouche, L. Rooney and A. G. Barret, *J. Org. Chem.* 2012, **77**, 3060.
- 3 S. Sankaranarayanan, A. Sharma and S. Chattopadhyay, *Tetrahedron: Asymmetry* 2002, **13**, 1373.
- 4 T. Muller, D. Coowar, M. Hanbali, P. Heushling and B. Luu, *Tetrahedron* 2006, **62**, 12025.
- 5 N. Cohen, C. G. Scott, C. Neukom, R. J. Lopresti, G. Weber and G. Saucy, *Helv. Chim. Acta* 1981, **64**, 1158.
- 6 Q. Changgeng, C. Xiong and Z. Haixiao, U.S. Patent 20,090,076,006, May 19, 2009.
- 7 R. S. Givens, K. Stensrud, P. G. Conrad, A. L. Yousef, C. Perera, S. N. Senadheera, D. Heger and J. Wirz, *Can. J. Chem.* 2011, **89**, 364.
- 8 N. Kanoh, S. Kumashiro, S. Simizu, Y. Kondoh, S. Hatakeyama, H. Tashiro and H. Osada, *Angew. Chem., Int. Ed.* 2003, **42**, 5584.
- 9 I. Miyazaki, S. Simizu, H. Ichimiya, M. Kawatani and H. Osada, *Biosci., Biotechnol., Biochem.* 2008, **72**, 2739.
- 10 Y. Kondoh, K. Honda and H. Osada, *Methods Mol. Biol.* 2015, **1263**, 29.
- 11 A. Czarna, G. M. Popowicz, A. Pecak, S. Wolf, G. Dubin and T. A. Holak, *Cell Cycle* 2009, **8**, 1176.
- 12 J. D. Oliner, K. W. Kinzler, P. S. Meltzer, D. L. George and B. Vogelstein, *Nature* 1992, **358**, 80.
- 13 D. L. Lin and C. Chang, *J. Biol. Chem.* 1996, **271**, 14649.

Fig. S1. LC–MS Chromatograms of Purified Synthetic MDM2^{25–109} and MDM2^{TMR} Proteins.



HPLC Conditions: HPLC analysis was performed at 25 °C on a Cosmosil 5C18-AR300 preparative column (Nacalai Tesque, 4.5 × 250 mm) with a linear gradient of 30–50% CH₃CN containing 0.1% TFA at a flow rate of 1 cm³ min⁻¹ over 20min.

Fig. S2. Mass Spectrometry Data of Synthetic MDM2^{25–109} and MDM2^{TMR} Proteins.




Fig. S3. CD Spectra of Synthetic L-MDM2 and D-MDM2 Proteins. Spectra of L-MDM2^{25–109} and D-MDM2^{25–109} were measured at 25 °C in PBS containing 0.5 mmol dm⁻³ TCEP and 0.005% Tween-20 (pH 7.4).




Fig. S4. SPR Analysis of p53 Binding to Synthetic MDM2^{25–109}.




Table S1. Data of the Initial Chemical Array Screening.

Code name	L-MDM2	D-MDM2	Code name	L-MDM2	D-MDM2
NPD5176	+	-	NPD9453	-	++
NPD5180	+	-	NPD9481	-	++
NPD5494	+	-	NPD9515	-	++
NPD6517	+	-	NPD10099	-	++
NPD7843	+	-	Cromolyn	-	+
NPD8361	+	-	NP507	-	+
NPD8439	+	-	NP653	-	+
NPD12476	+	-	NP699	-	+
NPD12691	+	-	NP783	-	+
NP843 (1)	-	+++	NP846	-	+
NPD6370	-	+++	NP891	-	+
NPD9234	-	+++	NP897	-	+
Nystatin A1	-	++	NPD1967	-	+
Curcumin	-	++	NPD8611	-	+
NP627	-	++	NPD9100	-	+
NP637	-	++	NPD9120	-	+
NPD6878	-	++	NPD9150	-	+
NPD8700	-	++	NPD9399	-	+
NPD8908	-	++	NPD9580	-	+
NPD9098	-	++	NPD9657	-	+
NPD9268	-	++	NPD10038	-	+
NPD9315	-	++			

Hit compounds by chemical array screening had selective binding activity to L-MDM2^{TMR} or D-MDM2^{TMR} protein. Fluorescent intensity I of each spot was measured at 532 nm. The relative intensities (ΔI) of each compound were calculated from the difference between the fluorescence signals of L-MDM2^{TMR} and D-MDM2^{TMR} ($\Delta I = |I_L - I_D|$). The average (ΔI_{ave}) and standard deviation (SD) for all spots were also calculated. The compounds with a larger ΔI value than ' $\Delta I_{ave} + 1SD$ ' were determined to be selective compounds for L-MDM2 or D-MDM2. [+: >+1SD; ++: >+2SD; +++: >+3SD]. Because of the heterogeneous system of chemical array screening, the result of chemical array screening was not always consistent with that of homogeneous fluorescence polarization assay. Therefore, we should consider the possibilities that false positive signals (non-specific binding between the protein and array surface) and false negative signals (weak binding of the protein to randomly immobilized compounds) occurred in chemical array screening.

Fig. S5. Structures of Hit Compounds.




Table S2. Inhibitory Activities of Reference Compounds by a Fluorescence Polarization Assay.


Compound	IC_{50} (μ M)	
	L-MDM2	D-MDM2
L-P4	0.030 \pm 0.016	>1.0
D-P4	>1.0	0.019 \pm 0.004
Nutlin-3a	0.32 \pm 0.03	>30

Table S3. Inhibitory Activities of NP843 (**1a**) and *ent*-NP843 (**1b**) by SPR Analysis and ELISA.


Compound	IC_{50} (μ M)	
	SPR	ELISA
L-P4	0.011 \pm 0.001	0.066 \pm 0.007
D-P4	>1.0	>1.0
NP843 (1a)	>30	>30
<i>ent</i> -NP843 (1b)	3.1 \pm 0.5	16.7 \pm 1.1

Fig. S6. The Representative Dose-response Curves in the Binding Inhibition Assays: (A) FP Assay; (B) SPR Analysis; (C) ELISA.

(A)



(B)



(C)






Fig. S7. Results of Cell Growth Inhibition Assay.




C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata\`_•%-\p\F166TrtCO2Me_500H-1.als




```

DFILE F166TrtCO2Me_500H-1.als
COMNT single_pulse
DATIM 2015-05-01 10:07:41
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 KHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 21.9 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 44

```




C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata\`_•%-\p\F166TrtCO2Me_500C-1.als




```

DFILE F166TrtCO2Me_500C-1.als
COMNT single_pulse_decoupled_gated_NOE
DATIM 2015-05-01 10:55:43
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 KHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 22.2 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 54


```




C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata\`.*-p\G46TsCO2Me_500H-1.als




DFILE G46TsCO2Me_500H-1.als
COMNT single_pulse
DATIM 2015-05-01 12:06:02
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 21.6 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 44







C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata\`.*-p\G46TsCO2Me_500C-1.als





DFILE G46TsCO2Me_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-05-01 12:54:25
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 22.4 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 52







C:\Documents and Settings\-\iC\ffXfNfgfbfv\NMRdata\`_•¶-p\G46TrtTs_500H-1.als



C:\Documents and Settings\iGEM\ffffXfNfgfbfv\NMRdata\`_•I-p\G46TrtTs_500C-1.als




```

DFILE G46TrtTs_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-04-08 23:34:11
OBNUC 13C
EXMOD single_pulse_dec
OSFRQ 125.77 MHz
OBSET 7.87 KHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 21.9 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGATN 52


```

C:\Documents and Settings\iGQ\ffffXfNfgfbfv\NMRdata\`_•%p\G57OH_500H-1.als




DFILE G57OH_500H-1.als
COMNT single_pulse
DATIM 2014-10-29 15:17:34
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 20.5 c
SLVNT CDCL₃
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 38

C:\Documents and Settings\iGQ\ffffXfNfgfbfv\NMRdata\`_•%p\G57OH_500C-1.als




DFILE G57OH_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2014-10-29 16:05:47
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 21.1 c
SLVNT CDCL₃
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 52

C:\Documents and Settings\-\i@0\ffffXfNfgfbfv\NMRdata\`_•%-\p\G48OH_500H-1.als




DFILE G48OH_500H-1.als
COMNT single_pulse
DATIM 2014-11-04 10:30:30
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 20.8 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 38

C:\Documents and Settings\-\i@0\ffffXfNfgfbfv\NMRdata\`_•%-\p\G48OH_500C-1.als



DFILE G48OH_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2014-11-04 11:18:42
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 21.5 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 54


C:\Documents and Settings\-\iC\fffxFfNfgfbfv\NMRdata\`_•¶\G22CN_500H-1.als




```

DFILE G22CN_500H-1.als
COMNT single_pulse
DATIM 2014-10-31 10:34:04
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 KHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 22.2 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGATN 40

```




C:\Documents and Settings\-\i\x\fffXfNfgfbfv\NMRdata\`_•¶\G22CN_500C-1.als




```

DFILE G22CN_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2014-10-31 11:22:20
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 23.1 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
PCAIN 52


```




C:\Documents and Settings\-\i@0\ffffXfNfgfbfv\NMRdata\`_•%-\p\G49_500H-1.als




DFILE G49_500H-1.als
 COMNT single_pulse
 DATIM 2015-04-13 10:19:11
 OBNUC 1H
 EXMOD single_pulse.ex2
 OBFRQ 500.16 MHz
 OBSET 2.41 kHz
 OBFIN 6.01 Hz
 POINT 13107
 FREQU 7507.39 Hz
 SCANS 8
 ACQTM 1.7459 sec
 PD 5.0000 sec
 PW1 6.82 usec
 IRNUC 1H
 CTEMP 21.9 c
 SLVNT CDCL3
 EXREF 0.00 ppm
 BF 0.12 Hz
 RGAIN 38





C:\Documents and Settings\-\i@0\ffffXfNfgfbfv\NMRdata\`_•%-\p\G49_500C-1.als





DFILE G49_500C-1.als
 COMNT single pulse decoupled gated NOE
 DATIM 2015-04-13 11:07:11
 OBNUC 13C
 EXMOD single_pulse_dec
 OBFRQ 125.77 MHz
 OBSET 7.87 kHz
 OBFIN 4.21 Hz
 POINT 26214
 FREQU 31446.06 Hz
 SCANS 1000
 ACQTM 0.8336 sec
 PD 2.0000 sec
 PW1 3.50 usec
 IRNUC 1H
 CTEMP 22.4 c
 SLVNT CDCL3
 EXREF 77.00 ppm
 BF 1.20 Hz
 RGAIN 54





C:\Documents and Settings\-\ic\fffXfNfgfbfv\NMRdata\`_•¶-p\G22_500C-1.als




```


DFILE G22_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2014-09-06 16:09:23
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 23.7 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 54

```


C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata__•%p\G50re_500H-1.als




DFILE G50re_500H-1.als
COMNT single_pulse
DATIM 2015-04-13 15:08:10
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 22.0 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 40




C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata__•%p\G50re_500C-1.als




DFILE G50re_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-04-13 15:56:05
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 22.4 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 58




C:\Documents and Settings\-\i@0\ffffXfNfgfbfv\NMRdata\`_•%-\p\G185Br_500H-1.als




DFILE G185Br_500H-1.als
COMNT single_pulse
DATIM 2015-04-13 18:13:38
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 21.8 c
SLVNT CDCL₃
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 42









C:\Documents and Settings\-\i@0\ffffXfNfgfbfv\NMRdata\`_•%-\p\G185Br_500C-1.als





DFILE G185Br_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-04-13 19:01:31
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 22.4 c
SLVNT CDCL₃
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 54








C:\Documents and Settings\-\iC6\ffffXfNfqfbfv\NMRdata\`~ •¶\G30Bn 500C-1.als




C:\Documents and Settings\-\iE\fffXfNfqfbfv\NMRdata\`~ •¶\G52Bn 500H-1.als




```

DFILE G52Bn_500H-1.als
COMNT single_pulse
DATIM 2015-04-09 02:49:50
OBNUC 1H
EXMOD single_pulse.ex2
OSFRQ 500.16 MHz
OBSET 2.41 KHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 21.5 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 40

```




C:\Documents and Settings\-\iEÜ\fffXfNfgfbfv\NMRdata\~ •¶\G52Bn 500C-1.als




```

DFILE G52Br_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-04-09 03:37:48
OBNUC 13C
EXMOD single_pulse dec
OBFRQ      125.77 MHz
OBSET       7.87 kHz
OBFIN      4.21 Hz
POINT      26214
FREQU      31446.06 Hz
SCANS       1000
ACQTM      0.8336 sec
PD          2.0000 sec
PW1        3.50 usec
IRNUC      1H
CTEMP      21.8 c
SLVNT      CDCL3
EXREF      77.00 ppm
BF          1.20 Hz
PGATN      5.8

```




C:\Documents and Settings\iC6U\fffXfNfgfbfv\NMRdata\`_•¶\G53CHO_500H-1.als




```

FILE G53CHO_500H-1.als
COMNT single_pulse
DATIM 2015-04-09 04:44:00
OBNUC 1H
EXMOD single_pulse.ex2
OBFREQ 500.16 MHz
OBSET 2.41 KHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 21.5 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGATN 40

```




C:\Documents and Settings\-\iC\fffXfNfgfbfv\NMRdata\`_•¶\G53CHO_500C-1.als




```

DFILE G53CHO_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-04-09 05:31:57
OBNUC 13C
EXMOD single_pulse_dec
OEFRQ 125.77 MHz
OBSET 7.87 KHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 21.9 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 58


```




C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata__•%p\G52CHO_500H-1.als




DFILE G52CHO_500H-1.als
COMNT single_pulse
DATIM 2015-04-09 03:48:19
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 21.6 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 40




C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata__•%p\G52CHO_500C-1.als




DFILE G52CHO_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-04-09 04:36:16
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 21.8 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 58




C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata__•%p\G1700H_500H-1.als




DFILE G1700H_500H-1.als
COMNT single_pulse
DATIM 2015-02-23 13:30:55
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 21.1 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 48





C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata__•%p\G1700H_500C-1.als







DFILE G1700H_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-02-23 14:18:53
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 21.6 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 50






C:\Documents and Settings\i5\fffXfNfgfbfv\NMRdata\`_\`_p\G1710H_500C-1.als







C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata\`.*-p\G44_500H-1.als




DFILE G44_500H-1.als
COMNT single_pulse
DATIM 2015-04-08 23:50:41
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 21.5 c
SLVNT CDCL₃
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 44




C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata\`.*-p\G44_500C-1.als




DFILE G44_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-04-09 00:38:38
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 21.8 c
SLVNT CDCL₃
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 54




C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata__•%p\G113Br_500H-1.als




DFILE G113Br_500H-1.als
COMNT single_pulse
DATIM 2015-04-09 00:51:17
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 21.4 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 44





C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata__•%p\G113Br_500C-1.als






DFILE G113Br_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-04-09 01:39:14
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 21.9 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 58







C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata\`_*%~p\G177_DiOHre_500H-1.als









C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata__•\p\NP843_500H-1.als




C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata__•\p\NP843_500C-1.als






C:\Documents and Settings\-\iC\fffXfNfgfbfv\NMRdata\`_•¶-p\G180_cyclo_500H-1.als




```

FILE G180_cyclo_500H-1.als
COMNT single_pulse
DATIM 2015-04-22 19:05:57
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 KHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 22.0 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGATN 42

```




C:\Documents and Settings\-\i@ú\fffXfNfgfbfv\NMRdata\`_•¶-p\G180_cyclo_500C-1.als







```



DFILE G180_cyclo_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-04-22 19:54:17
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 22.5 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGATN 54



```

















C:\Documents and Settings\iGEM\fffXfNfgfbfv\NMRdata\`_•¶\G163_product_Proton-1-1.als




```

FILE G163_product_Proton-1-1.als
COMNT single_pulse
DATIM 2015-02-12 10:57:34
OBNUC 1H
EXMOD proton.jxp
OBFRQ 399.78 MHz
OBSET 4.19 KHz
OBFIN 7.29 Hz
POINT 13107
FREQU 7598.78 Hz
SCANS 8
ACQTM 1.7249 sec
PD 5.0000 sec
PW1 3.06 usec
IRNUC 1H
CTEMP 18.4 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGATN 34

```




C:\Documents and Settings\iGÜ\ffffXfNfgfbfv\NMRdata__*\p\G163_product_500C-1.als





```


DFILE G163_product_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-02-12 21:19:32
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ      125.77 MHz
OBSET      7.87 kHz
OBFIN      4.21 Hz
POINT      26214
FREQU      31446.06 Hz
SCANS       1000
ACQTM      0.8336 sec
PD          2.0000 sec
PW1        3.50 usec
IRNUC      1H
CTEMP      21.5 c
SLVNT      CDCL3
EXREF      77.00 ppm
BF          1.20 Hz
PGATN      52

```







C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata\`_*%p\G135_500H-1.als




DFILE G135_500H-1.als
COMNT single_pulse
DATIM 2015-04-14 12:08:18
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 22.2 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 40





C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata\`_*%p\G135_500C-1.als





DFILE G135_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-04-14 12:56:10
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 22.5 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 52



C:\Documents and Settings\iC6U\fffXfNfgfbfv\NMRdata\`_•¶\G134_500H-1.als







C:\Documents and Settings\-\iC\fffXfNfgfbfv\NMRdata\~_*¶-p\G134_500C-1.als




```

DFILE G134_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-04-14 11:06:53
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ      125.77 MHz
OBSET       7.87 KHz
OBFIN       4.21 Hz
POINT        26214
FREQU      31446.06 Hz
SCANS        1000
ACQTM       0.8336 sec
PD           2.0000 sec
PW1          3.50 usec
IRNUC      1H
CTEMP        22.6 c
SLVNT      CDCL3
EXREF        77.00 ppm
BF           1.20 Hz
RGAIN        54


```




C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata\`_•%p\G154_500H-1.als



DFILE G154_500H-1.als
COMNT single_pulse
DATIM 2015-02-04 14:19:13
OBNUC 1H
EXMOD single_pulse.ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.82 usec
IRNUC 1H
CTEMP 20.6 c
SLVNT CDCL₃
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 42



C:\Documents and Settings\iG0\ffffXfNfgfbfv\NMRdata\`_•%p\G154_500C-1.als



DFILE G154_500C-1.als
COMNT single pulse decoupled gated NOE
DATIM 2015-02-04 15:08:05
OBNUC 13C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 21.1 c
SLVNT CDCL₃
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 54

